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Abstract   
Women with an inherited BRCA mutation are at significantly increased risk for 
breast and ovarian cancer, often diagnosed at an earlier age than sporadic cancers.   
Prophylactic surgery, with bilateral mastectomy and/or bilateral prophylactic salpingo-
oophorectomy, represents an option for risk reduction.  The purpose of this study was to 
explore quality of life, sexual functioning, menopausal symptoms, psychological well-
being and satisfaction with risk management decisions for BRCA-positive women ages 
21 to 50 (M = 38.4 years), without a personal history of cancer.  A web-based, cross-
sectional study design was utilized to compare women opting for any prophylactic 
surgery (n = 160) with those without a history of prophylactic surgery (n = 71).  Quality 
of life (per the Quality of Life Index, Self-Anchoring Striving Scale and Body Image 
Quality of Life measures) and Psychological General Well-Being Index scores were 
essentially the same across the entire study sample.  While controlling for age, 
prophylactic surgery (PS) predicted more severe symptoms of sexual dysfunction as 
measured by the Female Sexual Functioning Index (total score, Desire, Arousal, 
Lubrication and Satisfaction domains).  Similarly, PS predicted menopausal symptoms 
and sleep difficulties.  Women who had not undergone any prophylactic surgery had 
higher levels of Stigma and lower levels of Mastery, as measured by the BRCA Self-
Concept scale.   Prophylactic surgery also predicted higher levels of Satisfaction with 
Decision for hereditary cancer risk management.  Findings from this exploratory study 
provide insight into the quality of life, sexual functioning and psychological well-being 
vi 
 
for unaffected, BRCA-positive women.  Additional research is needed to examine sexual 
functioning prospectively, to further investigate the potential sequelae of risk-reducing 
surgery. 
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Chapter 1 
Introduction 
During 2011 it is estimated over 230,000 women will be diagnosed with invasive 
breast cancer and over 21,000 women with ovarian cancer in the United States alone 
(American Cancer Society, 2011).  About 10% of all breast and ovarian cancers are due 
to hereditary factors (Ferla et al., 2007; Lynch, Silva, Snyder, & Lynch, 2007).  
Hereditary breast and ovarian cancer (HBOC) is most often attributed to a genetic 
mutation in either the BRCA1 or BRCA2 gene.  Estimates are that deleterious mutations 
in BRCA account for 30% to 50% of all hereditary breast cancers (Ferla et al., 2007; 
Lynch, Silva, Snyder & Lynch, 2007) and 80% of all hereditary ovarian cancer cases 
(Majdak, 2005).   
Other inherited mutations inferring an increased risk of breast cancer include 
PTEN (Cowden disease), ATM (ataxia-telangiectasia mutation), CHEK2, p53 (Li-
Fraumeni syndrome) (Smith & Isaacs, 2007) and hereditary diffuse gastric cancer 
(HDGC) (Pharoah, Guilford, & Caldas, 2001).  Hereditary ovarian cancer can be 
associated with inherited mutations in Hereditary Non-Polyposis Colon Cancer (HNPCC) 
or Lynch Syndrome (Petrucelli, Daly, & Feldman, 2011).   
Genetics 
 The fundamental unit of heredity is the gene (Clark & Russell, 2000).  Genes are 
found in the nucleus of the cell, and composed of deoxyribonucleic acid (DNA).  The 
DNA is organized in chromosomes of varying size.  A chromosome is a very long single 
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double-stranded DNA molecule made up of many genes and tightly folded until it is 
about 5 microns in diameter.  The chromosomes contain the genes, which have a 
particular sequence of the A, T, G, or C bases.  The sequence of the base pairs provides 
instructions to the cell for making proteins (Stansfield, Colome & Cano, 2003).   
Genetic mutations.  An allele is a minor variation in a gene.  Human cells have 
two duplicate sets of 23 different chromosomes, for a total of 46.  However, the germ-line 
cells (egg and sperm cells) contain a single copy of each gene.  We receive one allele of 
each gene from each parent.  The wild-type allele is the one most often seen.  A mutant 
allele is the result of a genetic alteration in the sequencing of the A, T, G or C bases of 
DNA.  During gene replication, any error within a DNA molecule leading to the 
insertion, deletion or substitution of one or more bases will result in a mutation.  A 
somatic or acquired mutation refers to an alteration which is not inherited (Kumar, Abbas 
& Fausto, 2003).   
Hereditary Breast and Ovarian Cancer   
Historical accounts of the 18th century document descriptions of breast cancer 
cases clustered among young, related family members (Cady, 1970; Handley, 1938).  
Other family pedigrees recorded male breast cancers and descriptions suggestive of 
ovarian or peritoneal cancers (Everson et al., 1976; Marger, Urdaneta, & Fischer, 1975).  
Lynch et al. (1984) among others questioned whether a hereditary form of breast cancer 
existed, one distinctly different from sporadic breast cancers.  Epidemiologic studies 
supported the hypothesis of a familial risk; however, options for further evaluation were 
limited by technical expertise.  Biomarker research was deemed a priority to enhance the 
identification of those individuals at increased risk (Lynch & Kullander, 1987).   
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 In 1990, Hall et al. conducted a genetic analysis of individuals in 23 Caucasian 
families with 146 cases of early-onset breast cancer.  That research led to the discovery of 
a specific gene at the q21 position on chromosome 17 associated with an increased 
susceptibility to inherited breast cancer.  The mutation would come to be known as the 
BRCA1 gene, after further identification of the mutation in families with multiple cases 
of breast cancer (Miki et al., 1994).  Identification of the BRCA2 breast cancer 
susceptibility gene on chromosome 13 (13q12-q13) followed shortly thereafter (Wooster 
et al., 1994) and was cloned one year later (Wooster et al., 1995).  The BRCA acronym is 
derived from the words “breast cancer”, although the mutation also infers an increased 
risk of ovarian cancer.  In the United States testing is currently performed by only one 
facility, the Myriad Genetics Laboratories.   
The BRCA genes are inherited in an autosomal dominant pattern, and mutations 
can be inherited from either biological parent.  One normal or wild-type allele would be 
inherited from the parent without a mutation.  BRCA1 and 2 are tumor suppressor genes, 
involved in repair of DNA damage by coding for particular proteins involved in cell-
cycle progression, chromatin remodeling, apoptosis and ubiquitylation (Friedenson, 
2005; Narod & Foulkes, 2004).   
Risk 
An inherited, or germline mutation in one allele of either BRCA1 or BRCA2 
confers a lifetime breast cancer risk of 70-85% (Lynch, Shaw & Lynch, 2004; Ray, 
Loescher & Brewer, 2005).  A 40-50% lifetime risk of ovarian cancer is associated with 
the BRCA1 mutation, and a 20-30% risk with the BRCA2 mutation (Russo et al., 2008; 
King, Marks & Mandell, 2003).  This is a significant difference relative to the general 
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population, with a 12% lifetime risk for breast cancer and 1.4% for ovarian cancer 
(American Cancer Society, 2011).  In addition, BRCA mutations are also associated with  
an increased risk for melanoma, pancreatic, uterine, gallbladder, bile duct and stomach 
cancers (Thompson & Easton, 2002; Van Asperen et al., 2005), as well as fallopian tube 
and primary papillary serous carcinoma of the peritoneum (Aziz et al., 2001; Casey et al., 
2005).  
Breast and ovarian malignancies typically occur at a younger age in women with 
a BRCA mutation in comparison to those without a mutation.  Indications for a referral to 
genetic counseling include a personal or family history of early-onset breast cancer 
(premenopausal or less than age 50), bilateral breast cancer, male breast cancer, 
Ashkenazi Jewish heritage, and/or ovarian cancer at any age (Allain, 2008; Godfrey & 
Chlebowski, 2008; USPSTF, 2005).  
Risk management.  Increased surveillance and risk-reducing strategies are 
available for individuals at increased risk for hereditary breast and ovarian cancer.  
Management options include surveillance with regular breast imaging with 
mammography, breast-dedicated magnetic resonance imaging (MRI) and focused breast 
ultrasound (Smith & Isaacs, 2007).  The goal of these strategies is early detection, rather 
than primary prevention.  Risk reduction with chemoprevention includes oral 
contraceptive pills, tamoxifen or raloxifene.  Prophylactic surgeries, including removal of 
the breast tissue (mastectomy) and/or removal of the fallopian tubes and ovaries (bilateral 
salpingo-oophorectomy) are also options recommended to minimize risk of developing a 
malignancy (Hartmann, et al., 2001; Meijers-Heijbor, et al., 2001; Rebbeck, Kauff & 
Domcheck, 2009).  Current National Comprehensive Cancer Network (NCCN, 2011) 
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clinical guidelines recommend risk-reducing, bilateral prophylactic mastectomy (BPM) 
be considered only for women with a BRCA mutation, or other evidence of significant 
familial cancer risk.   
 Ovarian cancer is notoriously difficult to detect in the early stages.  Ovarian 
cancer symptoms are typically absent early in the disease process, as are accurate 
screening tests (Coates, Kolor, Stewart & Richardson, 2008).  Consequently, the majority 
of ovarian malignancies are diagnosed at later stages resulting in a decreased survival 
rate.  For women at increased risk of hereditary breast ovarian cancer, the NCCN clinical 
guidelines (2011) recommend bilateral prophylactic salpingo-oophorectomy (BPSO) 
between the ages of 35 and 40, after child bearing, or based on family history considering 
the earliest age of an ovarian cancer diagnosis.   
 Uptake of contralateral prophylactic mastectomy in women diagnosed with breast 
cancer has been estimated at 50% (Schwartz et al., 2008).  The rate of BPSO in women 
with a BRCA mutation (BRCA+) has been similar at 49% (Meijers-Heijboer et al., 
2003).  A more recent retrospective study at one United States medical center examined 
medical records for 90 BRCA+ women (Stuckey et al., 2010).  Of those, 42% were 
unaffected.   Fifty-three percent of unaffected women, those without a personal history of 
cancer, chose to have prophylactic surgery (BPM and/or BPSO).    
 The NCCN guidelines for surveillance in the absence of BPSO recommend 
regular pelvic ultrasound imaging and CA-125 blood levels, with the understanding of 
the limitations and low sensitivity of these screening modalities.  Decisions regarding the 
timing of risk-reducing, prophylactic surgeries can play a critical role in disease 
prevention, morbidity and mortality.  Occult malignancies have been detected in women 
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at the time of elective, risk-reducing surgeries (Khurana, Loosmann, Numann & Khan, 
2000; Lamb, Garcia, Goff, Paley & Swisher, 2006; Stuckey et al., 2010).   
Significance of Study  
Inherited mutations in the BRCA gene dramatically increase the risk of breast and 
ovarian cancer.  Unaffected women, those with a BRCA mutation and no personal history 
of cancer, face complex and challenging decisions which require accurate, evidence-
based information and appropriate psychosocial support.  Prophylactic surgical 
interventions are irreversible.  To contribute to our limited knowledge of these 
psychosocial sequelae of prophylactic, risk-reducing surgeries an exploratory study was 
conducted.     
Purpose and Specific Aims 
The purpose of this cross-sectional study was to compare BRCA+ women who 
have had any prophylactic, risk-reducing surgery with those who have not had any 
prophylactic surgery.  Variables included quality of life, body image quality of life, 
sexual functioning, menopausal symptoms, psychological well-being, BRCA self-concept 
and satisfaction with the decision for risk management.   
Aim (1).   To compare self-reported socio-demographics, quality of life, body 
image quality of life, sexual functioning, menopausal symptoms, psychological well-
being and BRCA self-concept differences between BRCA-positive women electing any 
prophylactic, risk-reducing surgery and those who have not had prophylactic surgery.   
Aim (2).   To determine the level of satisfaction with the decision for risk 
management based on the research participants’ choice for prophylactic surgery, 
chemoprevention, and/or clinical surveillance. 
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Aim (3).  To examine the potential moderating role of prophylactic surgery on the 
relationships between sexual functioning, psychological well-being, BRCA self-concept, 
body image quality of life and quality of life.  
Theoretical Framework  
The schema model of self-concept provided the theoretical framework for this 
research.  Self-schemata are “cognitive generalizations about the self, derived from past 
experience”, providing an organizing framework to process information about the self 
(Markus, 1977).  Some self-conceptions are positive, while others are negative.  Some 
represent the present time, and others characterize past or future experiences.  
Additionally some self-representations reflect what we could be, the possible future self 
(Markus & Wurf, 1987).  This middle-range theory is based on the cognitive approach to 
social psychology, encompassing structural and functional components of the self-
concept (Stein, 1995).  The dynamic self-concept mediates both intrapersonal processes 
(affect and motivation) and interpersonal processes (social perception and interaction 
strategy) and the perception/response to one’s situation (Markus & Wurf, 1987).    
Definitions 
Body image.  Body image is a complex, multidimensional component of the self 
image encompassing perceptions and attitudes about one’s own body, although not 
exclusively related to physical appearance (Cash, 2004).  The body image schema is 
conceptualized as a component of the self-concept schemata. 
Body image quality of life.  Body image quality of life refers to the impact of 
one’s perceptions of self on an individual’s psychosocial quality of life.  Body image 
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quality of life is measured by the Body Image Quality of Life Inventory (Cash & 
Fleming, 2002).      
Prophylactic surgery.  Prophylactic surgery refers to elective surgical procedures 
to prevent the occurrence of disease, measured by self-report.  Examples of prophylactic 
surgery include a bilateral prophylactic mastectomy (surgical removal of the breast 
tissue) with or without breast reconstruction and/or salpingo-oophorectomy (removal of 
the fallopian tubes and ovaries) with or without a hysterectomy (removal of the uterus) 
(http://www.merriam-webster.com/medlineplus/prophylactic). 
Psychological well-being.  Psychological well-being refers to a “sense of 
subjective well-being or distress” (Revicki, Leidy & Howland, 1996).  Six affective states 
are included:  anxiety, depressed mood, positive well-being, self-control, general health 
and vitality.  The Psychological General Well-Being Index was the instrument used to 
measure well-being in the current study.          
Quality of life. Quality of life as defined by Ferrans and Powers (1992) is a 
“person’s sense of well-being that stems from satisfaction or dissatisfaction with the areas 
of life that are important to him/her” (p. 29).  The Quality of Life Index was based on a 
conceptual model developed from qualitative research.   
Satisfaction with decision.  Satisfaction refers to the individual participant’s 
level of satisfaction with their health care decision (Holmes-Rovner, et al., 1996), relative 
to the choice for either prophylactic surgery or surveillance due to an inherited risk of 
breast and ovarian cancer.   
Self-concept. The definition of self-concept is based on the self-schemata 
conceptualization (Markus, 1977; Markus & Wurf, 1987; Stein, 1995).  The self-concept 
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is a dynamic structure and process, representing a frame of reference about one’s self 
based on past experiences, present views of the self and the possible self-- a sense of 
what we may become in the future.     
Sexual functioning.  Sexual functioning was evaluated by the Female Sexual 
Function Index (FSFI), a self-report measure of desire, subjective arousal, lubrication, 
orgasm, satisfaction, and pain (Rosen et al., 2000).  These domains reflect those currently 
used for the diagnosis of female sexual dysfunction disorders (Sobczak, 2009).  
Unaffected.  The term unaffected refers to an “individual who does not manifest 
any symptoms of a particular condition” (Gene Reviews, n.d.).   Individuals with an 
inherited genetic predisposition to a particular disease state who have not been diagnosed 
with that disease, are considered unaffected.  For example, those individuals at increased 
risk for hereditary breast and ovarian cancer due to an inherited BRCA mutation without 
any personal history of cancer are unaffected.  This was measured by self-report.   
Summary   
Inherited mutations in BRCA genes have been characterized as significantly 
increasing the lifetime risk for breast and ovarian cancer, malignancies which often occur 
earlier than sporadic cancers.  Women with a BRCA mutation who develop cancer are 
typically diagnosed prior to the age of natural menopause.  Prophylactic surgeries and 
chemoprevention are options for risk reduction, but not without consequences.  The 
challenging decisions related to risk management merit the opportunity for informed 
consent.  Accurate and timely information, counseling related to cancer risk and risk-
management options, and psychosocial support are important for the decision-making 
process.  This exploratory study was conducted to contribute to our knowledge of the 
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quality of life, body image quality of life, sexual functioning, menopausal symptoms, 
psychological well-being, and satisfaction with risk-management decisions in this high-
risk population.   
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Chapter 2 
Literature Review 
This chapter of the dissertation provides a review of the literature focused on 
choices for and outcomes of prophylactic, risk-reducing surgery in women at increased 
risk for hereditary breast and ovarian cancer (HBOC), most often attributed to a 
hereditary mutation in the BRCA gene.  Research studies were identified by multiple 
computerized literature searches of the following databases:   CINAHL, PsycINFO, 
PubMed and Cochrane.  Keyword combinations included:  BRCA, genetic testing, 
hereditary breast ovarian cancer syndrome, prophylactic mastectomy, oophorectomy, 
cancer screening, surveillance, risk reduction, body image, sexuality, sexual functioning, 
intimacy, anxiety, and quality of life.  Additional articles were found after review of the 
studies found in the original database searches.  
Risk Reduction 
Chemoprevention, or cancer risk reduction using medication, is one option for 
decreasing the risk of breast and ovarian cancer due to a BRCA mutation.  Oral 
contraceptives, tamoxifen and raloxifene are examples of chemoprevention.  Oral 
contraceptives reduce the risk of gynecologic cancer (fallopian tube and/or ovarian) by 
5% for each year of use (Whittemore et al., 2004).  Use of oral contraceptives for 6 years 
or more is associated with an odds-ratio of 0.62.  Furthermore, there does not appear to 
be any increased risk for breast cancer associated with oral contraceptive use.  The oral 
contraceptives may actually reduce breast cancer risk slightly in those with a BRCA-1 
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mutation (Milne et al., 2005).  Tamoxifen and raloxifene are selective estrogen receptor 
modulators (SERMs), which block estrogen from breast tissue cells.  Only limited data 
are available on the use of these medications for primary prevention of breast cancer in 
BRCA+ women.        
The most profound risk reduction in this population is accomplished by 
prophylactic surgery, or removal of the tissues at risk for cancer prior to the diagnosis of 
a malignancy.  A meta-analysis of bilateral prophylactic salpingo-oophorectomy (BPSO) 
in BRCA mutation carriers found a strong association in risk reduction for breast, ovarian 
and fallopian tube cancers (Rebbeck, Kauff & Domchek, 2009).  The meta-analysis of 10 
studies found an 80% reduction for gynecologic cancer and a 50% risk reduction for 
breast cancer.   
Bilateral prophylactic mastectomy has demonstrated a significant reduction in risk 
for breast cancer by other researchers as well (Hartmann et al., 2001; Meijers-Heijboer et 
al., 2001; Rebbeck, Kauff & Domcheck, 2009).  Rebbeck et al. (2004) reported BPM 
decreased breast cancer risk by 90% in those with intact ovaries, and 95% in women with 
a previous history of BPSO.  Kramer et al. (2005) found BPSO was associated with a 
62% reduction in breast cancer risk in BRCA1 carriers (n = 673).  The most profound 
benefit was seen in women electing BPSO at premenopause (HR = 0.38).  Risk reduction 
was also seen in BRCA1 carriers with BPSO prior to the age of 40 (OR = 0.36) by Eisen 
et al. (2005).  When examined together, BRCA1/2 carriers had a significant reduction in 
risk within 15 years of BPSO (OR = 0.39).  Kauff et al. (2008) published data from a 
prospective, multicenter trial enrolling 1,079 unaffected BRCA+ women choosing either 
observation or BPSO.  BPSO in that study was associated with a 72% reduction in 
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BRCA2-associated breast cancer risk and an 85% reduction in BRCA1-associated 
gynecologic cancer risk at three years of follow up.   
Domchek et al. (2010) reported their findings for a prospective, multi-center 
cohort study with 2,482 women evaluating risk and mortality reduction in BRCA carriers.  
Women in 22 centers across North America and Europe were followed from 1974-2009.   
No breast cancer was seen in unaffected women who opted for BPM, in comparison to a 
7% breast cancer incidence in those women without BPM (mean follow up of 3 years).  
A reduction in risk for ovarian cancer was seen with BPSO.  During 6 years of 
prospective follow up, no ovarian cancer was seen in unaffected BRCA2 carriers.  The 
hazard ratio for ovarian cancer in BRCA1 mutation carriers was 0.31 (95% CI:  0.12, 
0.82).  Six women (2%) developed a primary peritoneal cancer after risk-reducing BPSO.  
Seven percent of the BRCA1 positive women and 3% of the BRCA2 positive controls, 
without BPSO, were diagnosed with ovarian cancer.  A risk reduction for breast cancer 
was also associated with BPSO in BRCA1 (HR = 0.63; 95% CI: 0.41-0.96) and BRCA2 
positive women (HR = 0.36, 95% CI: 0.16-0.82).  In addition, a reduction in all-cause 
mortality was observed in unaffected BRCA mutation carriers with BPSO (HR = 0.45, 
95% CI: 0.21-0.95).   
Predictors for risk-reducing surgery.  Why do some women choose 
prophylactic surgery?  Two studies in the Netherlands examined factors predictive for 
prophylactic surgery in high-risk women (Madalinska et al., 2007; Meijers-Heijboer et 
al., 2000).  Meijers-Heijboer et al. (2000) found parenthood to be a significant predictor 
for BPM, and age was the only significant predictor for BPSO.  Women opting for 
prophylactic surgery were older than those who did not.  In a longitudinal, observational 
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study of 160 BRCA+ women, predictors for BPSO versus surveillance were age, 
marriage, and postmenopausal status (Madalinska et al., 2007).  Tiller et al. (2002) also 
found age to be a significant predictor for the 23% of women who opted for BPSO in an 
Australian study (n =95).  In that same study, parity (children versus no children), the 
number of first and second-degree relatives with ovarian cancer, and breast/ovarian 
cancer anxiety as measured by the Impact of Event Scale were not significantly 
predictive.   
A retrospective study of 90 women followed in a high-risk clinic in the United 
States found 51% opted for prophylactic surgery (Stuckey et al., 2010).  Those who chose 
any risk-reducing surgery were more likely to carry a BRCA 2 mutation, had children, 
were married, employed, and had a personal history of breast cancer.  Occult disease was 
found at the time of prophylactic surgery in that study, including ductal carcinoma in situ 
of the breast (15%), invasive ductal carcinoma of the breast (8%), adenocarcinoma of the 
fallopian tube (3%) and ovarian adenocarcinoma (3%).   
In an exploratory, retrospective review at a cancer center in the United States, 132 
women were found to be BRCA+ (Uyei et al., 2006).  Sixty-two percent of a subset of 37 
unaffected BRCA+ women chose surveillance over prophylactic surgery.  Overall, 
women who were BRCA+, had a personal history of cancer and diagnosed at an earlier 
stage of disease were more likely to choose surgery.  In a post-test only study design, 
Metcalfe et al. (2005) examined predictors in unaffected women after BPM (n = 60).   
Vulnerability and psychological distress, as measured on a study-specific quality of life 
(QOL) instrument, were determined to be predictors for prophylactic surgery in that 
group.        
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A Danish study followed 306 unaffected BRCA+ women prospectively (Skytte et 
al., 2010).  The 10-year uptake for BPSO was 75% and 50% for BPM.  No difference 
was observed between BRCA1 and BRCA2 mutation carriers.  Again, age and parity 
were associated with a decision to undergo prophylactic surgery.  Younger women 
between 30 to 40 years old were more likely to choose BPM, while 90% of those opting 
for BPSO had children.   
A study in the Netherlands offered 163 unaffected BRCA mutation carriers 
participation in an educational-support group (Landsbergen et al., 2010). Women were 
then followed prospectively after disclosure of their genetic test results.  Forty-eight 
percent of the women chose to participate in the group.  The group participants were 
more likely to be interested in prophylactic mastectomy (34%) than non-participants 
(19%; p = 0.05) at baseline.  Of those with a preference for BPM, the educational-support 
group participants were more likely to undergo BPM within 2 years (89%), in contrast to 
the non-participants (63%).     
More recently, Schwartz et al. (2011) reported uptake for BPM after BRCA 
genetic testing was associated with greater cancer distress prior to genetic counseling, 
higher anxiety levels, a personal diagnosis of breast or ovarian cancer, and intact ovaries 
prior to genetic counseling (n = 465).  Predictors for BPSO were a history of breast 
cancer and age > 40 years.      
Quality of Life and Psychological Distress 
Genetic testing.  A high level of psychological distress was found in French 
Canadian women (n = 640) who underwent BRCA genetic testing in comparison with the 
general population, regardless of any personal cancer history (Dorval et al., 2008).  The 
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levels of distress were similar to those of women with a newly-diagnosed breast cancer.  
A longitudinal study of 126 women undergoing genetic testing found no difference in 
psychological distress between women with or without a cancer diagnosis (Smith et al., 
2008).  Levels of psychological distress in mutation carriers were diminished by 6 
months post-testing.  However, 39% of the women in the study had high distress levels at 
baseline, including depressive and anxious mood.   
A Canadian study examined cancer-related distress and risk perception in 2,080 
Ashkenazi Jewish women undergoing genetic testing (Metcalfe et al., 2010).  At one-year 
follow up, 1,516 women completed study questionnaires.  Cancer-related distress was 
increased for BRCA+ women as measured by the Impact of Event Scale.  The perceived 
risk of breast cancer  increased significantly for those with a BRCA mutation, with a 
mean of  41.1% (pre-test) and 59.6% (post-test) (p = 0.002).        
Prophylactic surgery.  The Toronto BRCA Self-Concept Scale (Esplen et al., 
2009) includes three factors relevant to coping:  stigma, vulnerability and mastery.  A 
study of 241 BRCA+ women found cancer-specific anxiety to be low among affected and 
unaffected women, regardless of a choice for prophylactic mastectomy, oophorectomy or 
both (Vodermaier, Esplen & Maheu, 2010).  Cancer-specific anxiety, assessed by the 
Impact of Event Scale, was associated with younger age.  Lower levels of anxiety were 
associated with higher levels of self-esteem and mastery.     
Overall the limited studies examining QOL in women at risk for HBOC 
undergoing prophylactic surgery have had inconsistent findings.  Research has typically 
included a heterogeneous population, including affected (diagnosed with cancer) and 
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unaffected women (without cancer) (Brandberg et al., 2004, 2008; Isern, Tengrup, 
Loman, Olsson & Ringberg, 2008; Madalinska et al., 2005; Robson et al., 2003).   
Bilateral prophylactic mastectomy.  A Swedish research study investigated 
health-related QOL and patient satisfaction in 61 women after BPM with immediate 
reconstruction; one-half with a prior breast cancer diagnosis (Isern et al., 2008).  Genetic 
testing had been completed for 48 of the 61 study participants, 27 of whom were 
BRCA+.  Instruments included the SF-36, the Hospital Anxiety and Depression scale, 
and a study-specific questionnaire.  Those women without cancer scored higher in the 
physical function, vitality and social function dimensions.   
In a preoperative study examining QOL and BPM in 56 women with a familial 
risk for breast cancer, 16 had a cancer history (Brandberg et al., 2004).  Those without a 
history of breast cancer were similar in comparison to a normative sample of Swedish 
women with regard to QOL, anxiety and depressive symptoms.  Metcalfe et al. (2005) 
examined QOL in 59 Canadian women without a history of breast cancer (21.7% 
BRCA+).  The QOL levels were slightly higher than those for the general population and 
for women with newly diagnosed breast or gynecologic cancers.  Metcalfe et al. (2005) 
also found a positive correlation between QOL and social support in a study of 59 
unaffected women; thirteen (21.7%) were BRCA+.  Difficulty with emotional adjustment 
was observed in structured clinical interviews with unaffected women (n = 19) expressing 
regret after BPM (Payne, Biggs, Tran, Borgen & Massie, 2000).   
Prophylactic bilateral salpingo-oophorectomy.  A number of studies have 
evaluated QOL after BPSO.  No difference in QOL was seen in high-risk women after 
BPSO compared with those undergoing gynecologic screening surveillance by 
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Madalinska et al., 2005.  In contrast, Elit et al. (2001) observed menopause-specific QOL 
was diminished after BPSO in a sample of 40 women.  Robson et al. (2003) found 
women with BPSO between ages 35 and 44 had lower scores than the age-matched 
general population on physical functioning, bodily pain, general health and the emotional 
role subscales.  Age at the time of BPSO did not affect QOL in a Norwegian study; 
however, a personal cancer history did (Michelson et al., 2009).          
A significant decrease in anxiety regarding ovarian cancer after BPSO was noted 
in unaffected, high-risk women (n = 120) at three years follow up (Tiller et al., 2002).  
Forty women with a family history of ovarian cancer opted for risk-reducing BPSO; 40% 
were BRCA+.  Higher levels of psychological distress were reported by those who were 
premenopausal at the time of surgery.   
Sexual Functioning 
Human sexual functioning is a complex process under psychoneuroendocrine 
influence.  The classification of sexual dysfunction is based on desire, arousal, orgasm 
and sexual pain disorders (Basson et al., 2000).  The National Health and Social Life 
survey of American adults (ages 18-59) found sexual dysfunction more prevalent in 
women (43%), in contrast to men (31%) (Laumann, Paik & Rosen, 1999).  A positive 
association was observed between sexual dysfunction and low physical/emotional 
satisfaction and low feelings of general happiness.  However, the causal order of that 
relationship was unclear.  Similar findings were seen by Davison et al. (2009) in a 
community-based study of 349 women (55% premenopausal).  Those reporting sexual 
satisfaction also had a higher overall sense of well-being.         
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Outcomes after surgery.  Sexual functioning is a major concern for many 
women after gynecologic surgery.   Findings in research involving otherwise healthy 
women without a BRCA mutation treated for benign disease have had inconsistent 
results.  One randomized trial found no difference in sexual or psychosocial adjustment 
among three groups (n =204) treated for dysfunctional uterine bleeding with 
hysterectomy, hysteroscopy or laser ablation (Alexander et al., 1996).  Another 
prospective study examined sexual functioning before and after hysterectomy for benign 
disease (n = 1101) (Rhodes et al., 1999).  Details regarding the preoperative diagnoses 
were not provided.  The frequency of sexual relations during the month prior to surgery 
was lower than at the 12 and 24 months postoperative time points.  After hysterectomy, 
vaginal dryness was reported as a persistent problem for 35.2% of the women and a new 
problem for 8.7%. 
The type of gynecologic surgery is another variable for consideration.  There was 
no difference in sexual functioning or quality of life in two groups of women (n = 135) 
treated for benign disease, randomized to either total hysterectomy or supracervical 
hysterectomy (Kupperman, 2005).  The outcome variable of sexual activity was similar in 
two groups in another randomized study (n = 177) (Thakar et al., 2002).  Satisfaction 
with sexual life was similar in yet another randomized trial (n = 246) (Gimbel et al., 
2003).   
Kupperman et al. (2007) found both impaired sexual functioning and diminished 
quality of life in women with pelvic pain and/or abnormal menstrual bleeding                 
(n = 1,493).  Five years after surgery women treated by hysterectomy with BSO             
(n = 3,397) had more interference in sexual function than those with ovarian conservation 
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(n = 2,305), while controlling for age and hormone replacement therapy (McPherson et 
al., 2005).  
Women at increased risk for hereditary breast and ovarian cancer.  Research 
evaluating sexual functioning in the high-risk, unaffected BRCA+ population is limited, 
particularly in the United States.  In a single-institution study examining sexual 
functioning after BPSO in 54 American women, the majority had a personal history of 
breast cancer (83 %) (Robson et al., 2003).  Sexual problems reported included vaginal 
dryness (58%), difficulty achieving orgasm (48.6%) and lack of arousal (43.2%).  In 
addition, these symptoms were significant predictors for dissatisfaction with the decision 
to undergo the risk-reducing surgical procedure.  Satisfaction with sexual functioning was 
diminished moderately (42.1%) to extremely (53.7%) after BPSO in a sample of 40 
women (Elit et al., 2001).   
A breast cancer diagnosis was not an exclusion criterion in a European study that 
evaluated QOL and sexual functioning after BPSO (Madalinska et al., 2005).  Increased 
discomfort, decreased pleasure, and more endocrine symptoms were seen in the BPSO 
group (Madalinska, 2005).  Both sexual discomfort and diminished libido were more 
significant in women after BPSO, irrespective of hormone replacement use (Madalinska 
et al., 2006).  Sexual dysfunction, dyspareunia, and diminished pleasure/sexual 
satisfaction were seen after BPSO (Madalinska et al., 2005; Robson et al., 2003) and after 
BPM (Brandberg et al., 2008; Metcalfe, Esplen, Goel & Narod, 2004).  Vaginal dryness 
(35.2%) and pain with sex (27.7%) were a problem on average of 23.8 months after 
BPSO (Robson et al., 2003).  Negative effects related to the sexual relationship and 
feelings of femininity after BPM have also been documented (n = 114) (Bresser et al., 
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2006).  Moderate-to-extreme sexual functioning symptoms affected 42-53% of women 
after BPSO (n = 23) including diminished sexual desire, vaginal dryness and intimacy 
avoidance in a mixed-methods study (Elit, Esplen, Butler & Narod, 2001).  Fifteen 
percent of the women had been treated for breast cancer.  Sexual satisfaction was 
diminished, despite the use of hormone replacement. Participants suggested information 
related to the potential side effects of surgery was important in the decision-making 
process prior to surgery.  Premenopausal women reported greater psychological distress 
than those who were postmenopausal at the time of BPSO. Sexual functioning was a 
significant predictor of satisfaction with the decision to have BPSO, while 34% of 
women indicated a decline in sexual function after surgery (Robson et al., 2003).     
A prospective study examined sexual functioning in two groups:  women 
choosing BPSO (n= 38) and those opting for surveillance (n = 37) (Fang et al., 2009).  
Women with a personal history of breast cancer were included in both study groups.  
Individuals in the surgical group reported greater discomfort during sexual intercourse 
and lower levels of sexual satisfaction; findings were more profound in younger, 
premenopausal women.  Overall QOL was similar for both the surgery and surveillance 
groups.       
High-risk women without any personal history of cancer (n = 168) were followed 
in a multicenter study (Geiger et al., 2007).  Due to an increased risk for breast cancer, 
106 underwent BPM and of those 84% chose breast reconstruction.  Interestingly, QOL 
was not associated with prophylactic surgery.  However, diminished QOL was correlated 
with dissatisfaction with sex life for women with or without BPM.        
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A retrospective study of 98 BRCA+ women post-BPSO found the most common 
postoperative symptoms were:  vaginal dryness (52.1%), changes in libido (50%), sleep 
disturbances (46.7%), changes in sex life (43.9%), and hot flashes (42.9%) (Campfield, 
Moyer, & Matloff, 2011).  Women with BRCA mutations have concerns about the 
potential impact of prophylactic surgery on their sexuality and report little preoperative 
discussion on the topic (Matloff, 2009).  Some report feeling guilty about initiating the 
conversation, considering they should just be grateful they can avoid cancer.   The 
experience “represents an enormous amount of loss---not just future childbearing, but 
femininity, sexuality.  It’s like you’ve got a gun to your head and there is no other 
option” (Matloff, 2009, p.16).        
Body Image 
Research evaluating sexual function inevitably must also address the concept of 
body image.  Body image was found to predict sexual satisfaction in an internet-based 
study of 154 women (Pujols, Meston & Seal, 2010).  The instruments used in that 
research included the Female Sexual Functioning Index (FSFI) and Sexual Satisfaction 
Scale for Women.  Sexual satisfaction was strongly correlated with sexual functioning   
(r = 0.59); the FSFI arousal domain had the strongest association (r = 0.59).   
 Hopwood et al. (2000) evaluated body image in 45 women after BPM, utilizing a 
combination of psychiatric interviews and written questionnaires.  Almost 47% of the 
women were dissatisfied with their bodies at one year after BPM.  Over half of the 
women felt less sexually attractive and were self-conscious about their appearance.   
Lodder et al. (2002) developed a study-specific questionnaire to address these 
questions.  Sixty-three women without a personal history of cancer underwent genetic 
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testing; 26 were found to be BRCA+.   Of the BRCA+ women, 2 had BPM, 12 opted for 
BPM and BPSO, and the other 12 chose breast surveillance.  All 63 women were 
evaluated prior to testing and at one-year follow up.  At the one-year follow up, the BPM 
group had the highest levels of anxiety (29%) and cancer-related distress.  Differences in 
satisfaction with body image and intimate relationships were seen between the groups, 
with the lowest levels of satisfaction in the BRCA+ women undergoing BPM.  Despite 
this, the majority were satisfied with their decision to have prophylactic surgery.      
Summary 
The risk-reducing benefits of prophylactic surgery with BPM and/or BPSO have 
been documented.  However, a review of studies addressing psychosocial factors relative 
to risk-reducing surgery finds a paucity of research evaluating the long-term implications 
of prophylactic surgery (Fang, McKenzie, Miller & Daly, 2005).  In a systematic review 
of studies on prophylactic mastectomies, the need for more information on the emotional 
impact and psychosocial support for women and their partners has been highlighted 
(Lostumbo, Carbine, Wallace & Ezzo, 2008).   
The majority of research to date has not focused on unaffected women at 
increased risk for hereditary breast and ovarian cancer.  Sexual functioning in this high-
risk population is relatively unexplored.  Women need support and information about the 
potential risks and benefits of management and risk-reducing options (Babb et al., 2002).  
Unaffected BRCA+ women, without any personal history of cancer, face complex 
decisions regarding elective surgical procedures which are irreversible, and not without 
risk.  Research on the psychosocial implications relative to prophylactic surgery has been 
limited, particularly in the unaffected BRCA+ population in the United States.    
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Chapter 3 
Method 
 Chapter Three presents a discussion of the method used in this study.  Included 
are a description of the study design, study sample, recruitment strategy and the research 
instruments.  
Study Design 
To contribute to our limited knowledge of the psychosocial sequelae of 
prophylactic surgery in women at increased risk for hereditary breast and ovarian cancer, 
an exploratory study was conducted.  This research used a two-group cross-sectional, 
web-based survey design.  The goal was to recruit women without a personal history of 
cancer, who had completed genetic testing for HBOC with BRACAnalysis® testing, and 
found to have a deleterious mutation or a variant of undetermined significance in either 
BRCA1 or BRCA2.   Women who had completed any prophylactic surgery (BPM and/or 
BPSO) were compared with those who had not undergone any prophylactic surgery.  As 
a web-based study, the participants were able to complete all research instruments online, 
affording a unique level of privacy and anonymity.     
Sample 
 
The study sample consisted of a homogenous group:  BRCA+ females who were 
unaffected mutation carriers, without any personal history of cancer (other than non-
melanoma skin cancer).  Other inclusion criteria for study participants were:  ages 21 to 
50 years old (inclusive), literate and fluent in the English language, and access to a 
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computer or other internet-accessible device.  The age limitations for participation were 
chosen to contribute to homogeneity of the sample, essentially representing what would 
be a premenopausal age group.   
Two groups of women were included in the study:  women choosing surveillance 
(with or without chemoprevention) and women who had any prophylactic, risk-reducing  
surgery.  As the purpose of this study was to explore issues relevant to high-risk females 
who are candidates for prophylactic surgery, no males or women under the age of 21 
were included in the research.   
Procedures  
 Institutional Review Board.  This study was approved by the University of 
South Florida (USF) Institutional Review Board (IRB) and qualified for a waiver of the 
requirements for documentation of informed consent (IRB#: Pro00000842).  The 
document of informed consent included contact information for any participant questions, 
concerns or complaints.   
Web-based survey development.  All study instruments were incorporated into a 
single online survey using Checkbox ® 4.6 Web Survey Software.  The USF Information 
Technology department was consulted for training in the software program required to 
create the survey.  After development, the web-based survey was initially tested for 
functionality, clarity, and average time for completion by both lay individuals and health 
care personnel (20 minutes on average).   Appropriate revisions were completed prior to 
the initiation of study recruitment.  The Checkbox Survey program offers password-
protected data security and has reporting capabilities for data collection into Excel or 
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SPSS-compatible formats.  (Please refer to the Web-Based Survey Development Task-
List, Appendix A.)     
Recruitment.  Participants were initially recruited from a convenience sample of 
individuals attending a conference for education and support regarding hereditary breast 
and ovarian cancer.   The annual Joining FORCEs Against Hereditary Cancer Conference 
is a collaboration between H. Lee Moffitt Cancer Center and Research Institute in 
Tampa, Florida and the national non-profit organization Facing Our Risk of Cancer 
Empowered (FORCE).  Moffitt Cancer Center is the only National Cancer Institute 
designated cancer center in the state of Florida.  Also based in Tampa, the mission of 
FORCE is to improve the lives of individuals and families affected by hereditary breast 
and ovarian cancer. FORCE has a national e-mail and print mail distribution list of 
13,000 people.  The FORCE website and message boards contain the largest collection of 
personal experiences from this high-risk community.  The annual conference is the only 
national conference by and for this high-risk community and was held in Orlando, Florida 
from June 23 to June 25, 2011. A letter of support was obtained from the FORCE 
organization.     
At the 2011 FORCE conference, an announcement regarding the research study 
was made from the podium during the opening session by Dr. Sue Friedman, the founder 
and President of the Board of Directors for FORCE.  All recruiting materials were IRB-
approved, including a slide shown on the large screen during the opening session.  The 
slide, essentially a duplication of the study flyer, was also shown in a rotating sequence 
on the same screen at intervals throughout the conference.  Tote bags for all conference 
attendees included book marks and paper flyers regarding the study.  The research study 
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flyer included photographs of racially-diverse women, in an effort to recruit minorities 
into the study.  Study flyers were intended for attendees who might be interested in the 
study, or to share with other friends or family members who might qualify for the 
research.  The recruiting materials included information regarding the purpose of the 
study, eligibility criteria, contact information for any questions and a link to access the 
web-based study (www.previvorstudy.info).  The intention was to make study access 
simpler than typing in the original, lengthy URL required to access the research study on 
the USF web site at http://hsccm2.hsc.usf.edu/checkbox/Survey.aspx?surveyid=5721.  
Other recruiting materials used at the conference included tent cards placed throughout 
the hotel meeting rooms used during various conference sessions.  
Another effort to include a racially and ethnically diverse study sample involved 
making computers available at the conference.  Some conference attendees received 
scholarships for assistance with travel and conference registration expenses.  Space was 
secured at the conference hotel for individuals who were interested in completing the 
study while attending the conference.  Three high-top tables with chairs, lap-top 
computers and internet access were provided for interested individuals.  A water cooler 
and drinking cups were available in the same location.  The web-based survey included 
the informed consent document.  Printed copies of the informed consent were made 
available for women attending the conference.  After the conference, study participants 
were encouraged to print out the consent for their own records.   
During recruitment at the conference, a member of the research team was 
available to answer questions, provide technical assistance with the lap top computers 
and assist participants with accessing the research study online if necessary.  Potential 
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study participants were advised of the highly confidential (anonymous) nature of the 
information shared.  Interested parties were able to access the study link, review the 
informed consent and if they chose to, were able to proceed with the survey.  Participants 
were afforded privacy and left undisturbed if they did not have any questions.  Study 
participants were not required to complete the study once they had started and could skip 
items in the survey if they chose to.  The only questions requiring a response were the 
following:   
It is up to you to decide whether you want to take part in this study. If you want to 
take part, please sign the electronic form, if the following statements are true.       
I freely give my consent to take part in this study. I understand that I am agreeing 
to take part in research. All of my responses will be completely anonymous. I 
have printed a copy of this form for my own records. Would you like to 
participate in this study?   
The requisite response to this item was “yes”, in order to proceed with the survey.  
Clicking yes was considered an electronic signature.  No names or identifying 
information were collected.   
The other question requiring a response was:  “Have you had any type of cancer, 
other than a non-melanoma skin cancer?”  That item required a response of “no” in order 
to continue participation in the research study.  Any participants who indicated a personal 
history of cancer, other than non-melanoma skin cancer, then saw the final page of the 
study.  The information on that screen included a thank you for participating message and  
reinforced the message of  anonymity for all study participants.   
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Subsequent to the conference, additional study recruitment was primarily through 
web-based announcements, approved and posted by FORCE on the organization’s 
website (http://www.facingourrisk.org).  In an effort to enhance recruitment, in 
September of 2011, announcements regarding the study were also posted on the website 
for another organization for women affected by hereditary breast and ovarian cancer, 
Bright Pink (http://www.bebrightpink.org).   
Compensation.  All study participants had the option of submitting their e-mail 
address for participation in a random drawing for a $100 electronic gift card.  Completion 
of the entire study survey was not requisite for participation in the drawings.  In an effort 
to maintain anonymity for the participants, any interested individuals were encouraged to 
submit their e-mail address to a separate e-mail account created specifically for the 
research study (BRCAecard@gmail.com).  If the participants chose to participate in the 
drawing, they received an automated e-mail response thanking them for their 
participation in the study.  A total of 5 random drawings for $100 gift cards were 
scheduled at regular intervals, based on study accrual.  Winners of the random drawings 
were notified by e-mail.  They were able to access and redeem the electronic gift cards 
directly at http://amazon.com.   
Although all data collected through the web-based research survey was 
anonymous, the electronic data files have been maintained in a secure, password-
protected location.  The list of e-mail addresses submitted for the random drawings are  
kept in a separate password-protected electronic file.     
Additional resources.  Research questions regarding sexual functioning could 
have been perceived as sensitive and private in nature.  As the research was web-based, 
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participants had the opportunity to select a private setting to complete survey.  To address 
the potential for survey items which could elicit uncomfortable feelings or health-related 
questions, participants were encouraged to seek appropriate resources.   
The names of resources and electronic links for mental health services and 
domestic violence were  included in the online survey.  Participants were advised of the 
option to call “911”, a national service.  Contact information regarding Mental Health 
America, a national non-profit organization was provided.  Local community resources, 
treatment information, and support groups are available on the Mental Health America 
website (www.mentalhealthamerica.net).  A link for community resources for any 
domestic violence concerns was provided for the National Domestic Violence Hotline, 
available 24/7 by telephone or on the web (www.ndvh.org).  The National Domestic 
Violence organization offers services for crisis intervention, safety planning, referrals, 
and information.  Additional links for the FORCE website included a confidential, peer 
support toll-free helpline for individuals concerned about hereditary cancer, available at 
1-866-288-RISK (7475); (www.facingourrisk.org).  For other questions about any health 
issues, information was provided with a link for www.healthfinder.gov. 
Diversity.  The targeted enrollment of ethnically and racially diverse study 
participants (Table 1) was based on the Myriad Genetics’ clinical database (Hall et al., 
2009).   Myriad Genetics is currently the only laboratory offering the BRACAnalysis® 
genetic testing for BRCA mutations.  Between November 1996 and March 2006, the 
majority of individuals tested were of Western or Central European ancestry (87.4%).  
Middle Eastern women were tested the least often (1.1%).  Those of Latin American 
ethnicity were 4.2% and African Americans were only 3.8% of the women tested during 
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that time frame (Hall et al., 2009).  Numerous socioeconomic and psychosocial barriers 
to genetic services for underserved populations have been identified (Forman & Hall, 
2009).          
Table 1  
 
Targeted Enrollment 
Ethnic/Racial Categories    Sex/Gender 
      Females Males     Total 
Hispanic or Latino      17  0    17  
Not Hispanic or Latino    383  0  383 
 
Ethnic Category:  Total of All Subjects  400  0  400 
 
American Indian/Alaska Native       6  0      6 
Asian        11  0    11 
Native Hawaiian or Other Pacific Islander      0  0      0 
Black or African American     17  0    17 
White      366  0  366 
 
Racial Category:  Total of All Subjects  400  0  400 
 
Measures 
 
Demographics and health history.  Self-reported socio-demographics, personal 
medical history and a family cancer history were obtained through a study-specific 
questionnaire developed by the researcher (Appendix B).  The readability for this 
measure was at the 6.8 grade level (Flesch-Kincaid).   
Quality of Life Index.  This scale measures QOL as defined by Ferrans and 
Powers (1992) and refers to a “person’s sense of well-being that stems from satisfaction 
or dissatisfaction with the areas of life that are important to him/her” (p. 29).  The Quality 
of Life Index (QLI) is based on a conceptual model developed from qualitative research.  
Exploratory factor analysis was utilized to determine the domains of health and 
functioning, social and economic, family, and psychological/spiritual (Ferrans, 1996).  
The QLI consists of two sections of 33 items each.  The first section addresses 
32 
 
satisfaction with items in each of the domains, while the second focuses on the 
importance of those items to the individual.  Satisfaction responses are weighted with the 
paired importance score.  The total score reflects overall quality of life.  Respondents 
answer on a 6 point Likert-type scale and the answers are scored based on a 
computational formula which provides an overall quality of life score, and 4 subscores 
for the domains.  Internal consistency reliability for the total score has ranged from 0.73 
to 0.99 among 48 studies.  The authors report alphas for the subscales of health and 
functioning (0.87), social and economic (0.82), family (0.77), and psychological/spiritual 
(0.90) (Ferrans & Powers, 1992).  In the current study, the Cronbach alpha coefficient for 
the QLI total score was 0.95.  The alphas for the subscales in the current study were:  
health and functioning (0.87), social and economic (0.85), family (0.78), and 
psychological/spiritual (0.80). The computation commands for SPSS are available 
(Ferrans & Powers, 2010).  Readability is at the 6.6 grade level (Flesch-Kincaid). 
Numerous disease-specific versions of the QLI have been developed, and translated into 
multiple languages.  This study used the Quality of Life Index, Generic Version III, with 
the author’s permission (Appendix C).     
Self-Anchoring Striving Scale.  Developed by Cantrill (1965), the Self-
Anchoring Striving Scale (SASS) is a subjective, single-item measure utilizing a visual 
scale in the form of a ladder, with response options from 10 to 1. The following 
description accompanies the ladder scale.  “We all desire certain things out of life.  When 
you think about what really matters in your own life, where on the ladder would you 
place your life at the present time?”  Ten represents the best one could imagine, and 1 is 
the worst one could imagine (Appendix D).  The measure yields one score, with a range 
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of 1 to10.  The SASS has also been used in other studies to measure quality of life 
(Beckie & Hayduk, 1997).  However, the focus of that analysis was the use of structural 
equation modeling to investigate the dimensionality of QOL.  The Flesch-Kincaid 
readability for the SASS is at the 3.9 grade level.   
Dyadic Adjustment Scale.  The original Dyadic Adjustment Scale (DAS) 
(Spanier, 1976) was a 32-item scale with subcales for dyadic satisfaction, consensus, 
cohesion and affectional expression.  A Revised Dyadic Adjustment Scale (RDAS) with 
14 items was developed with a total score Cronbach’s alpha of 0.90 (Busby, Christensen, 
Crane & Lason, 1995).  The 3 subscales for the RDAS are dyadic satisfaction, consensus 
and cohesion.  Other researchers have developed even more concise versions of the DAS.  
One abbreviated version of the DAS was developed for use as a brief screening tool 
(Sabourin, Valois, & Lusier, 2005).  All 4 items of the abbreviated scale (DAS-4) came 
from the Satisfaction subscale of the original DAS.  The authors evaluated the measure 
with both clinical and community samples in 5 different studies.  A total of 8,256 married 
or cohabitating individuals were in those studies, which included comparisons with the 
original DAS and other revised versions.  The alphas for the DAS-4 ranged from 0.84 to 
0.91.   
 The current study included only one item from the DAS-4, rating the level of 
happiness in the relationship.  The responses range from extremely unhappy (0) to perfect 
(6).  This single item was seen in the present research survey by any participants 
indicating their relationship status as married or in a committed relationship with a 
partner (Appendix E).  The Flesch-Kincaid readability for this single item is at the 10.1 
grade level.   
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Body Image Quality of Life Inventory.  The specific dimension of body image 
to be investigated is an important consideration in selecting the appropriate measure 
(Thompson, 2004).  The focus of this research was quality of life and psychosocial well-
being.  Therefore, the Body Image Quality of Life Inventory (BIQLI) (Cash & Fleming, 
2002) was utilized with the author’s permission (Appendix F).  The instrument does not 
actually assess body image, but rather the effects of body image in various life domains, 
including social functioning, sense of self, and sexuality.  A 7-point bipolar scale is used 
to rate the impact of body image on 19 aspects of individuals’ lives, yielding one 
composite score.  There is a 7-point response format, ranging from -3 (very negative) to 
+3 (very positive).  Higher scores indicate a more positive influence of body image on 
quality of life.  The initial Cronbach’s alpha was 0.95, and test-retest reliability was 0.79 
over a 2-3 week time frame.  The instrument was further validated with college students 
of both genders (n= 603) (Cash, Jakatdar & Williams, 2004).  The measure was found to 
be internally consistent for both sexes.  Principal components analysis confirmed the 
unidimensional structure of the scale.  The Cronbach’s alpha for the BIQLI across 7 
studies has ranged from 0.94 to 0.96 (Cash & Grasso, 2005).  The alpha for the current 
study is 0.97.  The authors have reported the test-retest reliability with 107 college 
students at 0.82, confirming temporal stability for a 2-week time frame.  Measurement 
invariance of the BIQLI was confirmed in a sample of over 1,200 adults (Rusticus, 
Hubley, & Zumbo, 2008).  The researchers conducted multigroup confirmatory factor 
analyses for data collected from 422 men and 840 women ages 18-98.  Three age 
categories were analyzed.  Configural, metric and scalar invariance were evaluated and 
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the all three levels of invariance were met.  The BIQLI is appropriate to use across all age 
and gender groups and is at the 7.7 grade level for readability (Flesch-Kincaid).  
Female Sexual Functioning Index.  Sexual functioning was evaluated by the 
Female Sexual Function Index (FSFI), a 19-item, self-report measure of 6 domains over 
the previous 4 weeks:  desire, subjective arousal, lubrication, orgasm, satisfaction, and 
pain (Rosen et al., 2000).  The total FSFI score has a possible range of 2.0 to 36.0.  
Higher scores reflect less severe symptoms, or less dysfunction.  A score of zero in a 
domain indicates a lack of sexual activity during the previous 4 weeks (Appendix G).   
This was the first empirically validated instrument to assess female arousal and 
has a high degree of internal consistency, with Cronbach’s alpha values of 0.82 to 0.97 
reported.  The Cronbach’s alpha coefficient for the current study was 0.97.  The alphas 
for the FSFI subscales were:  desire (0.93), subjective arousal (0.97), lubrication (0.97), 
orgasm (0.95), satisfaction (0.89), and pain (0.98). 
Test-retest reliability is high for each domain at 0.79 to 0.86.  Scores are 
calculated for each domain and then multiplied by a specified domain factor.  The total 
score is obtained by adding all of the domain scores.  The instrument was developed on a 
sample of normal controls and women meeting the diagnostic criteria for female sexual 
arousal disorder (Meston & Derogatis, 2002).  This instrument is at the 10th grade level 
(Flesch-Kincaid).   
To elicit additional information relative to those participants who indicated a lack 
of sexual activity during the previous 4 weeks on the FSF, an additional item was added 
to the research survey.  Response options included the lack of a partner, lack of interest or 
36 
 
physical problems related to sex (for the study participant or partner) and other- with an 
opportunity to free text a response.   
Menopausal Symptom Scale.  The Menopausal Symptom Scale (MSS) was 
adapted from the Breast Cancer Prevention Trial Symptom Checklist (Ganz et al., 2000).  
The original 43-item measure was used to assess symptoms associated with menopause 
and/or tamoxifen use in the National Surgical Adjuvant Breast and Bowel Project 
(NSABP) P-1 clinical trial conducted to investigate the effect of tamoxifen on breast 
cancer incidence.  When used in a study of breast cancer survivors, the Cronbach alphas 
were 0.76 (hot flash subscale), 0.73 (vaginal subscale) and 0.76 (urinary subscale).   The 
MSS assesses menopausal symptoms experienced during the prior week, including:  hot 
flashes, night sweats, vaginal dryness, genital itching/irritation, pelvic pain, and difficulty 
with bladder control when laughing/crying or difficulty with bladder control at other 
times.  Participants respond how bothered they are by each symptom from not at all (1) to 
extremely bothered (5).  Neither a total score, nor any subscale scores were used for the 
MSS measure.  Each of the 7 symptoms was analyzed individually.   
One additional question was included in this research study to explore any 
problems related to sleep (difficulty falling asleep, sleeping through the night, waking up 
early).  The same MSS response scale was used for this one item (Appendix H).    
Readability for this measure is at a grade level of 6.5 (Flesch-Kincaid).   
Psychological General Well-Being Index (Revised).  Subjective well-being was 
measured by the Psychological General Well-Being Index (PGWBI), a 22 item self-
administered questionnaire including 6 subscales:  vitality, general health, self-control, 
positive well-being, depressed mood and anxiety (Revicki, Leidy, & Howland, 1996).  
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The PGWBI-revised version was used in this study (Appendix I).  Changes from the 
original measure by Revicki et al. (1996) include the wording format for the stem items 
(including frequency of experience), but not the response format.  The measure was 
originally developed by Dupuy (1984) for use in face-to-face interviews and then 
modified for self-administration.  The instrument has been used in numerous community-
based studies, including the National Health Examination study (n = 6,913).  The revised 
instrument still uses a 6-point Likert-type scale, with 0 the most negative response and 5 
the most positive well being.  Respondents were asked to rate their experiences over the 
prior one month.  Higher scores reflect greater levels of well-being and less distress for 
each scale.   A higher score on the depressed mood scale reflects a lower level of 
depressed mood, or greater well-being.   
Internal consistency has been documented with alpha coefficients of 0.90 to 0.96.  
The current study had a Cronbach alpha coefficient of 0.95 for the total PGWBI score.  
The alphas for the subscales in the current study were:  vitality (0.85), general health 
(0.66), self-control (0.64), positive well-being (0.86), depressed mood (0.84) and anxiety 
(0.89).  Levels of test-retest reliability at one week have ranged from 0.71 to 0.86.  
Correlation between the PGWBI and other measures has been documented, including the 
Zung Self-Rating Depression Scale (ZSRS) (-0.75) (Revicki, Leidy, & Howland, 1996).  
Readability for this measure is at the 4.9 grade level (Flesch-Kincaid).   
BRCA Self-Concept Scale.  The development of this instrument was based on 
individual interviews and focus groups with BRCA+ women (Esplen et al., 2009).  Both 
affected and unaffected individuals with a BRCA mutation were included in the two-
phase process of instrument development, refinement and validation.  The schema model 
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of self-concept provided the theoretical framework for the measure.  An individual’s self-
concept and definition of herself, or self-schema, mediates the response to BRCA genetic 
testing results and health behaviors.  The final version of the BRCA Self-Concept Scale 
(BRCA-SCC) uses a Likert-type scale, with 17 items (Appendix J).   Higher scores 
indicate a more negative self-concept.  Principal components analysis of the final BRCA-
SCC instrument revealed three factors.  The reported Cronbach's alpha for the total scale 
was 0.90.  The resulting Cronbach’s alphas for the 3 subscales were:  stigma (0.87), 
mastery (0.68) and vulnerability (0.76). No difference was found between women with or 
without a personal history of cancer on the mean self-concept scores.  Validating 
measures included the Impact of Event Scale and the Rosenberg Self-Esteem Scale to 
assess for convergent validity.  In the current study, the Cronbach’s alpha for the BRCA-
SCC total score was 0.86.  The alphas for the subscales were:  stigma (0.82), mastery 
(0.74) and vulnerability (0.67).  The Flesch-Kincaid readability for this measure is at the 
9th grade level.      
Satisfaction with Decision.  Individual satisfaction with the choice for risk 
management with prophylactic surgery, chemoprevention, and/or clinical surveillance 
due to elevated risk of breast and ovarian cancer was evaluated with the Satisfaction with 
Decision Scale (SWD) (Holmes-Rovner et al., 1996).  The SWD was originally 
developed using a sample of women regarding decisions related to hormone replacement 
therapy.   The 6-item scale provides one global satisfaction with decision score 
(Appendix K).  A Cronbach’s alpha of 0.86 was reported at the time of the initial 
instrument development.  The alpha for the current study was 0.97.  The Flesch-Kincaid 
readability is at the 8.6 grade level.      
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Analysis 
All statistical analyses were performed with SPSS (version 17.0).  Variables were 
screened for normality and appropriately transformed based on published 
recommendations (Tabachnick & Fidell, 2007).  Analyses were performed both prior to 
and after transformation.  No differences relative to statistical significance were seen in 
comparison of the two analyses.  Participants were not required to answer all of the study 
questions and could skip items without a prompt or reminder message.  Consequently, 
any missing data were not included in the analyses.  Those p values < .05 were 
considered statistically significant.  Statistical analyses included descriptive statistics, 
independent samples t-tests (two-tailed), hierarchical multiple regression, and bivariate 
analysis with Pearson product-moment correlation (Aim 1);   independent samples t-tests 
(two-tailed) and hierarchical multiple regression (Aim 2); independent samples t-tests 
(two-tailed), hierarchical multiple regression and analysis of variance (ANOVA) (Aim 3).   
Conclusion 
Study participants were able to complete all research instruments online and at 
their own pace.  After the informed consent, the instruments were presented in the 
following sequence:  the study-specific socio-demographics questionnaire, one-item from 
the Dyadic Adjustment Scale, family cancer history,  personal medical history and 
relevant surgical history, Satisfaction with Decision, Self-Anchoring Striving Scale, 
Menopausal Symptom Scale, BRCA Self-Concept Scale, Psychological General Well-
Being Index, Body Image Quality of Life Inventory, Quality of Life Index, and the 
Female Sexual Functioning Index (FSFI).  On the final web page of the study, an 
opportunity was given to provide comments by free text.  There were no space limitations 
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for the comment section.  An average of 20 minutes was required to complete all study 
materials.  The responses for some of the questions or study items were conditional.  
Consequently, for individuals without a history of surgery, the time to complete the 
survey was expedited.     
 
 
  
41 
 
 
 
Chapter 4 
Results  
This chapter addresses the results of the web-based research survey.  The original 
goal for study recruitment was 400 BRCA+ women, ages 21 to 50 (inclusive), unaffected 
(without a personal history of cancer), fluent and literate in English, and with computer 
access.  A total of 267 women enrolled in the study.  Of those, one woman had just 
recently tested negative for BRCA, another was 63 years of age and 32 others had a 
personal history of cancer (affected).  Therefore, n = 233 met the study inclusion criteria 
and completed the majority of the survey questions.  Two women completed a portion of 
the survey, but did not indicate their status with regard to prophylactic surgery.  
Consequently, those were deleted from any relevant analyses requiring prophylactic 
surgery status.   
Aim (1)   
To compare self-reported socio-demographics, quality of life, body image quality 
of life, sexual functioning, menopausal symptoms, psychological well-being and BRCA 
self-concept differences between BRCA+ women electing any prophylactic, risk-
reducing surgery and those who have not had prophylactic surgery.   
Participants.  Study participants were predominantly residents of the United 
States (n = 208); however, residents of Canada, Australia, Netherlands, Israel, Belgium, 
and Germany were also represented in the sample.  The initiation of study recruitment 
was at the FORCE Conference, and 56 women (24%) reported becoming aware of the 
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study there.  The remainder learned about it on a website (n = 94; 40.3%), by 
brochure/flyer (n =3; 1.3%), by word-of-mouth (n =3; 1.3%) or other (n = 71; 30.5%). 
Reflective of the Myriad Genetics clinical database (Hall et al., 2009), the study 
sample was predominantly Caucasian (98.7 %) (Table 2).  Other participants included 
African American (0.4%), Asian (0.4%), and American Indian/Alaskan Native (0.4%).  
Hispanic/Latinas made up 4.3% of the sample, and 14.6% of the women were of 
Ashkenazi Jewish heritage.  Most of the women (84.5%) were either married or in a 
committed relationship with a partner/significant other.   
Table 2  
Demographics:  All Participants  
Total sample:  n = 233 
     Age      M =   38.4 Range = 21-50 
 
Race 
 Caucasian    222  (98.7%) 
 African American       1    (0.4%) 
 Asian         1   ( 0.4%) 
 American Indian/Alaskan Native     1   ( 0.4%) 
 
Ethnicity 
 Hispanic or Latino   10    (4.3%) 
 
Ashkenazi Jewish heritage   34   (14.6%)   
 
Study participants reported their BRCA mutation, with the breakdown as follows:  
BRCA 1- deleterious mutations were 121 (51.9%), BRCA 2-deleterious were 101 
(43.3%), and a BRCA-variant of undetermined significance (VUS) was reported by 5 
(2.1%).  Women with a BRCA-VUS are often still considered high risk, and all 5 of the 
women in this study had elected to have prophylactic surgery.  One hundred percent of 
the sample had some family history of cancer.  Having a relative with cancer who 
undergoes genetic testing (the proband) is often the first step in the process leading to 
determination of a particular familial BRCA mutation.        
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The mean age for study participants was 38.4 years (range 21 – 50).  The sample 
was well educated; 16.7% attended some college, 38.6% had a Bachelor’s Degree, and 
36.5% had completed a Graduate Degree or Professional School. The remaining 5.6% 
were high school or technical school graduates, and one individual had completed middle 
school.  The majority of women worked outside of the home (78.5%).  Five women were 
actively seeking employment, and the others described themselves as homemakers, 
students, or retired.  Of the women who responded to the query (n =204), 98.5% had 
health insurance at the time of the study.  The majority lived within 25 miles of their 
primary health care provider (90.6%).  Around half (52.9%) participate in a support 
group or community forum.  Of those, 17.6% met in person and the other group 
participation was web-based (35.3%).   
Only 9 of the women in the study were current smokers; 76.8% drank alcohol, 
and the majority exercised on a regular basis (64.4%).  Fifty-one percent (n = 119) 
reported being followed in a high-risk clinic setting.  With regard to chemopreventive 
measures, 39 (16.7%) were on oral contraceptives, and only 4 women (1.7%) were taking 
tamoxifen.   
More than half of the study sample (68.7%) had a history of prophylactic, risk-
reducing surgery, n = 160.  The distribution of surgical procedures was:  BPM (n = 117; 
50.2%), BPSO (n= 108; 46.4%), and hysterectomy (n=62; 26.6%).  Forty women (17%) 
had BPM, BPSO, and hysterectomy (Table 3).     
An independent samples t-test (n = 227) comparing the mean age for women with 
a history of prophylactic surgery (PS) and those without surgery (NO PS) was conducted.  
There was a significant difference in age for the PS group (M = 40.7, SD = 6.5, n = 158) 
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and the NO PS group (M = 32.4, SD = 7.1, n = 69); t (225) = 8.54, p < .001.  Of the 
women who had not had any prophylactic surgery, 83% were planning on some type of 
risk-reducing surgical procedure in the future.  Twenty-four percent of the study 
participants expressed a desire to have children in the future.  Five women were pregnant 
at the time of completing the research survey.   
For those women opting for BPM, the average age at the time of surgery was 38.3 
years of age (range 23 to 49 years).  The average time since surgery after BPM was 
M=1.9 years (SD= 2.0; n = 107).  The average age for BPSO was 40.7 years (range 27 to 
50 years).  For participants missing data relative to the age at BPSO, the figures were 
derived from surrogate data, utilizing the last menstrual period (recorded in the 
gynecologic history).  The time since BPSO (with or without hysterectomy) was M =2.8 
years (SD= 2.6; n = 106).  The majority of BPSO procedures were completed 
laparoscopically (92%), with robotic-assistance for 15% of those.  The remainder of the 
BPSO surgical procedures were open laparotomies (7%).  Just over half (53%) of the 
women who had BPSO also had hysterectomies.           
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Table 3  
Demographics:  Any Prophylactic Surgery/ No Surgery  
 
                  Prophylactic Surgery (n = 160)      No Prophylactic Surgery (n = 71) 
  
Age   M =   40.7 (SD = 6.5)   M =   32.4 (SD = 7.1) 
Range = 24-50    Range = 21-49 
 
Marital Status 
  Single      27  (16.9%)    24     (33.8%) 
  Married  119  (74.4%)    41     (57.7%) 
  Separated      2    (1.3%)    ----  
  Divorced     12    (7.5%)      5      (7.0%) 
  Widowed  ----         ---- 
 
Unmarried/ 
  Partnered  18     (11.3%)    18     (25.4%)    
 
Nulliparous  35     (21.9%)    32     (45.1%) 
 
Desire children 
  in future  21     (13.1%)    31     (43.7%)    
 
Health insurance  
  @ present time  138   (86.3%)    62     (87.3%) 
 
BRCA     
  1   81     (50.6%)    40     (56.3%) 
  2   71     (44.4%)    30     (42.3%) 
  VUS     5      (3.1%)    ----  
  Unspecified       3      1    
 
Time since results 
Genetic testing 
  0-6 months    6     (3.8%)    15  (21.1%) 
  6-12 months  21  (13.1%)    20  (28.2%) 
  1-2 years  32  (20.0%)    11  (15.5%) 
  2-3 years  27  (16.9%)      8  (11.3%) 
  3-4 years  24  (15.0%)      9  (12.7%)    
  4-5 years  11    (6.9%)      4    (5.6%) 
  > 5 years  38  (23.8%)      4    (5.6%) 
 
 
PS   160     (68.7%) 
  BPM    117     (50.2%) 
  BPSO   108     (46.4%) 
  Hysterectomy    62     (26.6%) 
  BPM & BPSO    70     (30.0%) 
  BSO & Hysterectomy   56     (24.0%) 
  BPM, BPSO  
  & Hysterectomy                40     (17.0%) 
Note:  VUS= variant of undetermined significance; PS= prophylactic surgery; BPM= bilateral prophylactic 
mastectomy; BPSO= bilateral prophylactic salpingo-oophorectomy.   
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Quality of Life Index.  The possible range of scores for the QLI measure is 0-30.  
The range in this study sample was 8.7-29.2; M = 21.8, Mdn =22.8 (n = 233).  The 
subscales for this instrument are Health and Functioning, Social & Economic, 
Psychological/Spiritual, and Family.  Independent samples t-tests were used to examine 
the difference between the groups.  No statistically significant difference was seen 
between women in the PS group and the NO PS group on the total QLI or any subscale; 
with the exception of the Family subscale.  Per an independent samples t-test the PS 
group (M = 23.3, SD = 5.1, n =156) and the NO PS group (M = 21.5, SD = 4.7, n =70) 
were significantly different; t (224) = 2.49, p =.013.  The QLI Family subscale includes 
items of satisfaction/importance relating to:  children, family health and happiness, and 
one’s spouse, lover or partner.   
Hierarchical multiple regression examining the dependent variable of the total 
QLI score, while controlling for age, was not significantly predicted by prophylactic 
surgery.  However, the QLI Family subscale was predicted by prophylactic surgery in a 
similar analysis.  The total variance explained by the model as a whole was 4% (R2),       
F (2, 221) = 4.5, p = .012 (Table 4).   
Table 4 
 
Hierarchical Multiple Regression Analyses with Significant Results; 
Outcome Variable:  QLI Family Subscale    
 
Variable  R2 Adjusted R2   ΔR2   df       F    p    
QLI -Family  
Step 1 (Control)    
  Age   .03 .03  .03    
Step 2   
  PS   .04 .03  .01 2,221  4.5 .012* 
Note:  QLI = Quality of Life Index 
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Self-Anchoring Striving Scale.  Descriptive statistics for the entire sample        
(n = 228) found M = 3.7, SD = 1.5, Mdn = 4.00 (range 1– 8).  An independent samples    
t-test found no significant difference between the PS and NO PS groups on this QOL 
measure.  Hierarchical multiple regression analysis for the SASS, while controlling for 
age, was not statistically significant when PS was used as a predictor variable.   
Body Image Quality of Life Inventory.   The scores for this sample on the Body 
Image Quality of Life Inventory (BIQLI) ranged from – 40.2 to +54.2.  No statistically 
significant difference was seen between the PS group (M = 12.1, SD = 22.0, n =146) and 
the NO PS group (M = 16.6, SD = 22.2, n = 66) on independent samples t-test.  The 
hierarchical multiple regression analysis was not significant when BIQLI was examined 
with PS as a predictor, again controlling for age.  In addition, BIQLI was not significantly 
correlated with the variables for any prophylactic surgery, BPM, or BPSO when 
examined with a bivariate Pearson product-moment correlation.   
Dyadic Adjustment Scale.  No statistically significant difference was seen 
between the PS group (M = 4.8, SD = 1.6, n =140) and the NO PS group (M = 4.9,        
SD = 1.6, n =60) on independent samples t-test for the one-item DAS question related to 
the degree of happiness in the relationship (with spouse, partner or significant other).  
Nor were the results significant when the one-item DAS was examined with hierarchical 
multiple regression, controlling for age, with PS as the predictor variable.    
Female Sexual Functioning Index.  The possible range of 2.0 to 36.0 for the 
total FSFI score was reflected in this study.  Other FSFI descriptive statistics are reported 
in Table 5.   An independent samples t-test comparing the total FSFI score for the PS 
group (M = 21.5, SD = 9.3) and the NO PS group (M =25.0, SD = 9.0) found a significant 
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difference; t (189) = 2.46, p =.015.    Higher scores reflect less severe symptoms, or less 
dysfunction.   
Table 5 
Descriptive Statistics:  Female Sexual Functioning Index  
                                  N              Min           Max          Mean       SD 
___________________________________________________________________________________________________________ 
Desire                       229           1.2            6.0            3.1            1.3 
Arousal                     224              0            6.0            3.6            1.9 
Lubrication               219              0            6.0            3.8            2.1 
Orgasm                     221              0            6.0            3.5            2.1 
Satisfaction               209           0.8           6.0             3.9            1.7 
Pain                           222              0           6.0            4.0             2.3 
FSFI-Total                192           2.0          36.0           22.5            9.3 
Note:  FSFI= Female Sexual Functioning Index; higher scores reflect less sexual dysfunction.      
The findings were similar when the domains of Desire, Arousal, Lubrication and 
Satisfaction were examined with independent samples t-tests.  The women in the PS 
group had more severe symptoms (greater dysfunction) than the women in the NO PS 
group.  Significant differences were seen in the individual domain of Desire for the PS 
group (M =2.9, SD=1.3) and the NO PS group (M = 3.7, SD= 1.3), t (225) = 4.37,            
p < .001.  The Arousal domain was significantly different for the PS sample (M = 3.4, 
SD= 1.9) and the NO PS sample (M = 4.1, SD= 2.0), t (221) = 2.58, p =.01. The 
Lubrication domain scores for the PS group (M =3.7, SD= 2.0) and the NO PS group    
(M =4.3, SD= 2.2) were significantly different, t (216) = 2.04, p =.043. Similarly, the 
independent t-test for the Satisfaction scores in the PS group (M = 3.7, SD =1.7) and the 
NO PS group (M = 4.4, SD = 1.5) were significantly different, t (206) = 2.58, p =.011.  
On the whole, women who had any prophylactic surgery had more severe symptoms on 
the FSFI than the NO PS group. No significant differences were found in the Orgasm or 
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Pain domains of the FSFI on independent samples t-test.  The PS and NO PS group 
statistics are shown in Table 6.   
Table 6 
Group Statistics:  Female Sexual Function Index  
Variable   N  Mean   SD 
Desire 
 NO PS     69  3.7  1.3 
 PS   158  2.9  1.3 
Arousal 
 NO PS     68  4.1  2.0 
 PS   155  3.4  1.9 
Lubrication 
 NO PS     67  4.3  2.2 
 PS   151  3.7  2.0 
Orgasm 
 NO PS     67  3.7  2.0 
 PS   153  3.4  2.0 
Satisfaction 
 NO PS     63  4.4  1.5 
 PS   145  3.7  1.7 
Pain  
 NO PS   66  4.0  2.5 
 PS   155  4.0  2.3 
FSFI- Total    
 NO PS     58  25.0  9.0 
 PS   133  21.5  9.3 
Note:  NO PS = no prophylactic surgery; PS = prophylactic surgery.  Higher scores reflect less 
sexual dysfunction.    
 
Hierarchical multiple regression was used again in separate analyses, to examine 
the ability of any prophylactic surgery to predict the total FSFI score and each of the 
FSFI domains, while controlling for age (Table 7).  In the analysis for the total FSFI 
score, the total variance explained by the model as a whole was 4.7% (R2), F (2, 187) = 
4.6,  p = .012.  For the Desire subscale, the total variance explained by that model as a 
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whole was 8.7% (R2), F (2, 222) = 10.62, p = .003.  The Arousal domain of the FSFI was 
analyzed with hierarchical multiple regression, controlling for age.  The total variance 
explained by that model was 4.3% (R2), F (2, 217) = 4.84, p =.009. For the Lubrication 
domain of the FSFI, the total variance explained by that model was 4.7% (R2), F (2, 212) 
= 5.26, p =.006. The Satisfaction domain of the FSFI was also analyzed with hierarchical 
multiple regression, controlling for age.  The total variance explained by that model was 
4.3% (R2), F (2, 203) = 4.57, p =.011.  Similar multiple regression analyses with the 
Orgasm and Pain domains did not reach statistical significance.   
Although the one-item DAS question was not significantly different in the 
independent samples t-test for the PS and NO PS groups, it was significant when 
examining the total FSFI as a dependent variable.  Again controlling for age, the one-item 
DAS question was able to predict the total FSFI score in a hierarchical multiple 
regression analysis, with the total variance explained by that model at 13% (R2),              
F (2, 170) = 12.6,  p < .001 (included in Table 7).     
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Table 7 
 Hierarchical Multiple Regression Analyses with Significant Results:   
Outcome Variable FSFI and Subscales    
Variable  R2 Adjusted R2   ΔR2   df       F    p    
 
FSFI 
Step 1 (Control)     
  Age   .04 .03  .04 
Step 2   
  PS   .05 .04  .01 2,187  4.6 .012* 
 
Desire  
Step 1 (Control)  
  Age   .05 .05  .05 
Step 2 
  PS   .09 .08  .04 2,222  10.6 .003* 
 
Arousal 
Step 1 (Control)  
  Age   .03 .03  .03 
Step 2 
  PS   .04 .03  .01 2,217  4.8 .009* 
 
Lubrication 
Step 1 (Control)  
  Age   .05 .04  .05 
Step 2 
  PS   .05 .04  .001 2,212  5.3 .006* 
 
Satisfaction  
Step 1 (Control)  
  Age   .03 .03  .03 
Step 2 
  PS   .04 .03  .01 2,203  4.6 .011* 
 
FSFI  
Step 1 (Control)     
  Age   .04 .03  .04 
Step 2   
  DAS    .13 .12  .09 2,170  12.6 <.001* 
            
Note:  PS= any prophylactic surgery; dichotomous variable.  FSFI= Total Female Sexual 
Functioning Index score.  DAS= one item Dyadic Adjustment Scale.     
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The FSFI total score was further investigated using Pearson product-moment 
correlation coefficient (Table 8).  No significant correlations were found between the 
FSFI total score and the prophylactic mastectomy or hysterectomy variables.       
Table 8 
Pearson Product-Moment Correlations Among Female Sexual Functioning Index and Other 
Study Variables 
Variable     1    2    3   4   5    6    7    8 
1. FSFI    
2. Any PS  -.18*  
3. BPSO  -.22*     ͌ 
4. DAS   . 32*  -.04 -.11  
5. SASS  -.42*  -.07  .01 -.30* 
6. BIQLI   .40*  -.09  .02 .25* -.45* 
7.  QLI   .46*   .09  .03 .36* -.62*   .63* 
8.  BRCASCC   -.24* -.26* -.18* -.11  .44*  -.34*  -.55* 
9.  PGWBI  .48*   .09   .01 .33* -.64*  .52*   .76*  -.55* 
Note:  *p < .05; ( ͌ not computed, one of variables is constant); FSFI= Female Sexual Functioning 
Index; PS= prophylactic surgery; BPSO= bilateral prophylactic salpingo-oophorectomy; DAS= 
one-item Dyadic Adjustment Scale; SASS= Self-Anchoring Striving Scale; BIQLI= Body Image 
Quality of Life Index; QLI= Quality of Life Index (total score); BRCASCC= BRCA-Self 
Concept Scale (total score); PGWBI= Psychological General Well-Being Index (total score).   
   
Menopausal Symptom Scale.  Independent t-tests were used to examine each of 
the menopausal symptoms.   The hot flashes symptom was significantly different 
between the PS group (n =156), M=2.0 (SD = 1.2) and the NO PS group (n = 70), M=1.2 
(SD = 0.7); t (224) = - 6.2, p < .001.  In addition, the night sweats symptom was 
significantly different in the PS group (n =157), M=1.8 (SD = 1.1) and the NO PS group 
(n = 70), M=1.3 (SD = 0.8); t (225) = -3.6, p <.001.  The vaginal dryness symptom was 
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also significantly different for the PS group (n =154), M= 2.1 (SD = 1.3) and the NO PS 
group (n = 70), M=1.4 (SD = 0.8); t (198.8) = 4.917, p < .001.   No significant difference 
was seen between the groups for the other menopausal symptoms on the MSS using the 
independent samples t-tests.  The additional question regarding any problems related to 
sleep difficulty was analyzed with an independent t-test.  Difficulty sleeping was 
significantly different between the PS group (n =157), M= 2.8 (SD = 1.4) and the NO PS 
group (n = 70), M = 2.3 (SD = 1.3); t (225) = 2.96, p =.003.     
When PS was examined as a predictor in a hierarchical multiple regression, 
controlling for the variable of age, the menopausal symptom of hot flashes was again 
statistically significant.  The total variance explained by the model as a whole was 15.4% 
(R2), F (2, 221) = 20.09, p < .001.   The menopausal symptom of night sweats was 
similarly examined in a hierarchical multiple regression, controlling for the variable of 
age.  Prophylactic surgery was able to predict 8.1% (R2) in the model as a whole,             
F (2, 222) = 9.81, p < .001.  A similar analysis for the vaginal dryness symptom found 
13.1% (R2) of the total variance explained, F (2, 219) = 16.5, p < .001.   
Although not significantly different in the independent samples t-test, the 
symptom of difficulty with bladder control (while laughing or crying) was significant in 
the hierarchical multiple regression analysis controlling for age, as predicted by PS.  The 
total variance explained by the model as a whole was 5% (R2), F (2, 219) = 5.61,             
p = .004.  Findings were similar in the same analysis for the symptom of difficulty with 
bladder control (at other times):  5% (R2), F (2, 218) = 5.95, p = .003.  Another 
hierarchical multiple regression analysis to examine the symptom of sleep difficulties 
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was conducted.  The total variance explained by the model as a whole was 7.1% (R2),     
F (2, 222) = 8.48, p < .001. 
Table 9 
 Hierarchical Multiple Regression Analyses with Significant Results:   
Outcome Variable: Menopausal Symptoms 
Variable  R2 Adjusted R2   ΔR2   df       F    p    
 
Hot Flashes  
Step 1 (Control)     
  Age   .13 .12  .13 
Step 2   
  PS   .15 .15  .03 2,221  20.09 <.001* 
 
Night Sweats   
Step 1 (Control)  
  Age   .07 .07  .07 
Step 2 
  PS   .08 .07  .009 2,222  9.8 <.001* 
 
Vaginal Dryness    
Step 1 (Control)  
  Age   .12 .11  .12 
Step 2 
  PS   .13 .12  .01 2,219  16.5 <.001* 
 
Bladder Control  
(laughing/crying)    
Step 1 (Control)  
  Age   .04 .04  .04 
Step 2 
  PS   .05 .04  .005 2,219  5.6  .004* 
 
Bladder Control  
(other times)    
Step 1 (Control)  
  Age   .05 .05  .05 
Step 2 
  PS   .05 .04  .00 2,218  5.9  .003* 
 
Sleep Difficulties     
Step 1 (Control)  
  Age   .07 .06  .07 
Step 2 
  PS   .07 .06  .006 2,222  8.5  <.001* 
Note:  PS= any prophylactic surgery; dichotomous variable.   
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Psychological General Well-Being Index (Revised).  Analysis with independent 
samples t-test for the PGWBI total score found no statistically significant difference 
between the PS group (M = 74.83, SD = 18.03, n =143) and the NO PS group (M =71.13, 
SD = 17.95, n =59).  No significant difference was seen in comparison of the 2 groups on 
any of the PGWBI subscales.  There were no significant findings when the PGWBI was 
examined in a hierarchical multiple regression analysis with prophylactic surgery as a 
predictor variable, while controlling for age.  Results for 2 subscales are not reported, due 
to the low Cronbach’s alphas for self-control (0.64) and general health (0.66).  The 
PGWBI descriptive statistics for the entire sample are presented in Table 10.   
Table 10 
Descriptive Statistics:  Psychological General Well-Being Index  
Subscales and Total Score 
Scale    n Min  Max  Mean    SD 
Anxiety    225  0  25  16.2    5.1 
Depressed Mood 225  0  15   12.0    2.7   
Positive Well-Being  229  4  20  12.8    3.8   
Vitality   230  1  19  11.4    4.2  
PGWBI- Total  204 17  108  73.8  18.0 
Note:  PGWBI = Psychological General Well-Being Index 
BRCA Self-Concept Scale.  Independent samples t-test (n = 221) examining the 
total BRCA-SCC score were significantly different for the PS and NO PS groups.  There 
were also significant differences for each of the Mastery and Stigma subscales (Table 
11).  Vulnerability scores are not reported here, due to the low Cronbach’s alpha for the 
current study (0.67).  Higher scores on the BRCA-SCC reflect a more negative self-
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concept.  The PS group had lower scores, reflecting a greater mastery and lower sense of 
stigma, in comparison with the NO PS group.    
Table 11 
BRCA Self-Concept Scale:  Subscales and Total Score 
                               PS                 NO PS  
Score  n M    SD   n M    SD t  df p-value 
Mastery   157 7.7   4.0 69 9.5    4.2 2.95 224 .003* 
Stigma    158 24.6  9.7 69 29.5   9.8 3.50 225 .001* 
Total Score 153 50.3 16.9 68 60.2 16.4 4.16 219 <.001* 
Note:  *p< .05; PS = prophylactic surgery; NO PS = no prophylactic surgery  
In addition, separate hierarchical multiple regression analyses controlling for age, 
were used to examine the prediction of the BRCA-SCC total score and the Mastery and 
Stigma subscales by any prophylactic surgery (Table 12).  Each of these was statistically 
significant.  For the BRCA-SCC total score, the total variance explained by the model as 
a whole was 8.5% (R2), F (2, 217) = 10.05, p < .001.  For the Mastery subscale, the total 
variance explained by the model as a whole was 4% (R2), F (2, 222) = 4.57, p = .011.  
With the Stigma subscale, the total variance explained by the model as a whole was      
5.5 % (R2), F (2, 223) = 6.52, p = .002.   
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Table 12 
 Hierarchical Multiple Regression Analyses with Significant Results:   
Outcome Variable: BRCA-Self Concept Scale and Subscales      
Variable  R2 Adjusted R2   ΔR2   df       F    p    
 
BRCA-SCC   
Step 1 (Control)     
  Age   .06 .05  .06 
Step 2   
  PS   .09 .08  .03 2,217  10.05 <.001* 
 
Mastery    
Step 1 (Control)  
  Age   .003 -.001  .003 
Step 2 
  PS   .04 .03  .04 2,222  4.6  .011* 
 
Stigma     
Step 1 (Control)  
  Age   .03 .03  .03 
Step 2 
  PS   .06 .05  .03 2,223  6.5  .002* 
     
Note:  PS= any prophylactic surgery; dichotomous variable.  BRCA-SCC= BRCA-Self concept 
Scale total score. 
 
Aim (2)   
To determine the level of satisfaction with the decision for risk management 
based on the research participants’ choice for prophylactic surgery, chemoprevention, 
and/or clinical surveillance. 
Satisfaction with Decision.   The independent samples t-test (n = 225) compared 
the participants’ satisfaction regarding the decision on hereditary cancer risk 
management.  For women with a history of any prophylactic surgery (PS) (M = 26.9,    
SD = 5.9, n =154) and those without surgery (NO PS) (M = 24.2, SD = 6.1, n =71) there 
was a significant difference; t (223) = 3.06, p =.002.  Higher scores indicate a higher 
level of satisfaction with the decision.  No statistically significant difference was seen 
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when the prophylactic surgery subgroups were compared with independent samples t-
tests.   
Prophylactic surgery was predictive of the SWD outcome variable using 
hierarchical multiple regression, controlling for age (Table 12).  Total variance explained 
by the model as a whole was 4% (R2), F (2, 220) = 4.63, p = .011.  Multiple regression 
using time since surgery (BPM or BPSO) to predict the SWD score was not statistically 
significant.   
Table 13 
 Hierarchical Multiple Regression Analysis;    
Outcome Variable: Satisfaction with Decision       
Variable  R2 Adjusted R2   ΔR2   df       F    p    
 
SWD   
Step 1 (Control)     
  Age   .008 .004  .008 
Step 2   
  PS   .04 .03  .03 2,220  4.6  .011* 
 
Note:  PS= any prophylactic surgery; dichotomous variable.  SWD= Satisfaction with Decision.   
 
Study participants provided information regarding medications for chemo-
prevention, or risk reduction with prescription medications.  With regard to women 
taking oral contraceptives (n = 39; 16.7%), there was no significant difference in SWD 
seen for women in this subgroup when examined with independent t-test or with 
hierarchical multiple regression (controlling for age).  Only 4 (1.6%) of the study sample 
was taking tamoxifen for chemoprevention, so analysis for that subgroup was deferred.  
With regard to surveillance, no difference was seen in SWD for women followed in a 
high-risk clinic setting compared with those who were not with independent samples t-
test.   
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Aim (3) 
To examine the potential moderating role of prophylactic surgery on the 
relationships between the independent variables of the Total Female Sexual Functioning 
score, Global Psychological General Well-Being Index, Total BRCA Self-Concept score, 
Body Image Quality of Life, and the dependent variable of the Total Quality of Life 
Index score.    
Moderation, or a potential interaction of the variables, was evaluated in this study 
sample by first creating a centered product term for each relevant indicator.  This was 
achieved by subtracting the mean score from each variable and multiplying that value by 
the variable for any prophylactic surgery (yes/no).  This step was performed to minimize 
concerns regarding multicollinearity, or high intercorrelations between the independent 
variables.  Each centered product term was then used in multiple regression analyses, 
with the total QLI score as the dependent variable for the pairs (see Table 13 for the 
relevant descriptive statistics).   
Statistically significant main effects were found for the: BRCA-SCC, the Body 
Image Quality of Life Inventory/any prophylactic surgery, the Female Sexual 
Functioning Index/any prophylactic surgery, and the Psychological General Well-Being 
Index total score.  No statistically significant interaction effects were found for any of the 
interaction terms (Table 14).     
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Table 14 
 
Aim 3:  Descriptive Statistics 
  
Variable    n  Mean       SD  
Total QLI     233    21.8      4.5 
PS    231        .69      .46 
 
BRCA-SCC    223    53.4    17.3 
BRCA-SCC * PS   224       - 2.1    14.0 
 
BIQLI    214   13.8    22.6  
BIQLI * PS   217       -1.1    18.5 
 
FSFI    192  22.5      9.3 
FSFI * PS   204       -.67      7.5 
 
PGWBI    204  73.8    18.0 
PGWBI * PS      214     .71    14.7 
Note:  PS= any prophylactic surgery; dichotomous variable.  BRCA-SCC = total BRCA Self-Concept 
Score.  BIQLI= Body Image Quality of Life score.  FSFI= total Female Sexual Functioning Index score.   
PGWBI= total Psychological General Well-Being Index score.  
    
Table 15 
Aim 3:  Multiple Regression Analyses to Examine for Main Effects and Interaction Effects; 
Dependent Variable:  Total Quality of Life Index Score 
Variable       R2     Adjusted R2      β t df     F             p 
BRCA-SCC     -.53 -4.9         <.001* 
PS     -.06 -.97           .333  
BRCA-SCC * PS   -.04 -.42           .676  
Model       .31   .30    3,217  32.0      <.001* 
 
BIQLI     .56 5.8         <.001* 
PS     .14 2.7           .008*  
BIQLI * PS    .09 .99           .322  
Model       .42   .41    3,208  49.6      <.001*  
 
FSFI     .38 3.2           .002* 
PS     .16 2.5           .015* 
FSFI * PS    .13 1.0           .296 
Model      .24      .23    3,187  20.0      <.001* 
 
PGWBI    .74 8.6         <.001* 
PS     .02 .34           .732 
PGWBI * PS    .03 .29           .773  
Model      .58 .58    3,198  92.1      <.001*  
Note:  PS= any prophylactic surgery; dichotomous variable.  BRCA-SCC = Total BRCA Self-
Concept Score.  BIQLI= Body Image Quality of Life score.  FSFI= Total Female Sexual 
Functioning Index score.   PGWBI= Global Psychological General Well-Being Index score.        
β = standardized coefficient. 
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Twenty-seven percent of the participants had received their BRCA genetic testing 
results within the previous 1 year, while 18.5% were between 1 to 2 years, 15% from 2 to 
3 years, 14.2% from 3 to 4 years, 6.4% between 4 to 5 years and 18% had received their 
results more than 5 years prior.  Seventy-eight percent of the women had consulted with a 
Genetic Counselor prior to BRCA testing.   
Analysis of variance (ANOVA) was used to investigate for the presence of an 
interaction effect between the time since receiving genetic test results (ranging from 
intervals of 0 to 6 months to greater than 5 years) and prophylactic surgery (yes/no) 
relative to the total QLI score.  The analysis did not reveal statistical significance for an 
interaction, or any significant main effects for the two independent variables.   
  Summary. 
These data analyses address the findings for the 3 research aims of this 
exploratory study.  Please refer to Table 15 for a summary of the group statistics for all 
instruments.  The next chapter addresses these data in relation to previously published 
research.   
 
 
 
 
 
 
 
 
 
62 
 
Table 16 
 
Summary Table:  Group Statistics for All Study Instruments 
Instrument/ Subscales                                               # items                      Range                       n           Range-study           Mean (SD)                     α 
 
Quality of Life Index (QLI)       66   0-30  233 8.65-29.23  21.79 (4.46) 0.95 
Health & Functioning     13  0-30  231 5.62-29.88  21.49 (4.70) 0.87 
Social & Economic       8  0-30  228 5.00-30.00  22.22 (4.82) 0.85 
Psychological/Spiritual      7  0-30  230 6.86-29.17  21.24 (5.05) 0.80 
Family        5  0-30  228 3.40-30.00  22.76 (5.03) 0.78 
Self-Anchoring Striving Scale (SASS)      1  1-10  228 1-8    3.71 (1.46)    - 
Dyadic Adjustment Scale- 4 (DAS-1)              1  0-6  201 0-6     3.80(1.55)    - 
Body Image Quality of Life  
Inventory (BIQLI)      19           -57- +57  214 -40.16- +54.16 13.78 (22.60) 0.97 
 
Female Sexual Functioning Index (FSFI)    19  2.0-36.0  192 2.0-36.0  22.50 (9.33) 0.97 
Desire       2  1-5  229 1.2-6.0     3.10(1.33) 0.93 
Arousal       4  0-5  224 0-6.0     3.63(1.94) 0.97 
Lubrication      4  0-5  219 0-6.0     3.85 (2.09) 0.97 
Orgasm       3  0-5  221 0-6.0     3.50 (2.06) 0.95 
Satisfaction      3  0 (or1)-5  209 0.8-6.0     3.93 (1.69) 0.89 
Pain       3  0-5  222 0-6.0     3.97 (2.34) 0.98 
Menopausal Symptom Scale (MSS)     1-5 
Hot flashes      1    228 1-5  1.75 (1.10)  -  
Night sweats      1    229 1-5  1.62 (1.02)  - 
Vaginal dryness      1    226 1-5   .84 (1.20)  - 
Genital itching/irritation     1    227 1-5  1.44   (.82)  - 
Pain in pelvic area      1    227 1-4  1.28   (.65)  - 
Difficulty- bladder control     1    226 1-5  1.33   (.77)  -  
(while laughing or crying) 
Difficulty-bladder control      1    225  1-4  1.35   (.73)  - 
(at other times) 
Sleep problems        1    229 1-5  2.67  (1.38) - 
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Table 16 (continued) 
 
Summary Table:  Group Statistics for All Study Instruments 
Instrument/ Subscales                                               # items                      Range                       n           Range-study           Mean (SD)                     α 
 
Psychological General Well-Being 
Index (PGWBI)    22  0-110  204 17-108  73.77 (17.96) 0.95 
Anxiety      5  0-25  225  0-25  16.20 (5.13) 0.89 
Depressed Mood   3  0-15  225 0-15    11.97 (2.70) 0.84  
Positive Well-Being    4  0-20  229  4-20  12.82 (3.65) 0.86 
Self-Control   3  0-15  228  4-15  10.85 (2.66) 0.64 
General Health   3  0-15  224 2-15  10.60 (2.87) 0.66 
Vitality    4  0-20  230  1-19  11.35 (4.21) 0.85 
BRCA Self-Concept Scale (BRCA-SCC)  17  7-119  223 16-100  53.39 (17.26) 0.86 
Mastery      4  0-28  228  3-23  8.29   (4.12) 0.74 
Vulnerability    5  0-35  224  3-35  19.16 (6.83) 0.67 
Stigma     8  0-56  229  8-52  26.16 (9.97) 0.82 
Satisfaction with Decision (SWD)   6  6-30  227  6-30  26.03 (6.07) 0.97 
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Chapter 5 
Discussion  
Quality of Life 
Results from this web-based research study provide new data for a relatively large 
sample of women at risk for hereditary breast and ovarian cancer, in contrast to 
previously published studies.  Analyses with independent t-tests found a significant 
difference between the PS and NO PS group on the QLI Family subscale of the QLI, but 
not on any other QOL measures.  Controlling for age, the hierarchical multiple regression 
found PS was predictive of the QLI Family subscale.   
For the total QLI score (M = 21.8, SD 4.5; n = 233), the results are similar to the 
findings in a Norwegian research study examining QOL pre-operatively in women 
undergoing hysterectomy for benign disease (n = 111) and a control group (n = 173) 
(Rannestad, Eikeland, Helland & Qvarnstrom, 2000).  The total QLI score for the patients 
in that study was M = 22.11 (SD = 4.27) and for the healthy controls M = 22.98 (SD = 
3.93).  Sammarco (2001) used the QLI- Cancer Version in a study of women diagnosed 
with breast cancer under the age of 50 (years since diagnosis, M = 3.36, SD= 2.76,          
n =101).  The total QLI score for that group was M = 21.96, SD = 4.46.   
There were no significant differences for the SASS and BIQLI measures in the 
current study.  The results on the SASS were similar for both groups, with a mean score 
of 3.7.  As an exploratory study, there are no comparisons for this measure.  However, 
this finding does provide a basis for further inquiry.      
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Finch et al. (2011a)  assessed health-related quality of life with the Short Form 
Health Survey (SF-12) in a study of affected and unaffected BRCA+ women after BPSO 
(n =114).  Lower scores on physical functioning were reported for women with a 
previous history of breast cancer and those not taking any hormone replacement therapy.  
Mental health functioning was similar before and after BPSO, and at levels reported for 
the general population.     
Psychological Well-Being 
The PGWBI total score in the current study (n = 204) found the scores M =73.8 
(SD 18.0) reflect a high level of positive well-being, in comparison with national 
reference scores (McDowell & Newell, 1987).   
BRCA Self-Concept    
In the current study, there were statistically significant differences seen between 
women completing any prophylactic, risk-reducing surgery and those who had not had 
surgery in the BRCA Self-Concept scale (total score and all 3 subscales, Mastery, Stigma 
and Vulnerability).  However, the Cronbach’s alpha for the Vulnerability subscale in the 
current study was 0.67.  Mastery and vulnerability may be two sides of the same coin, 
another issue requiring further analysis.     
On the BRCA Self-Concept measure, the higher scores reflect a more negative 
finding.  For the total BRCA-Self Concept score, prophylactic surgery explained 8% of 
the variance.  Both Mastery and Stigma scores were higher for those women who had not 
had any prophylactic surgery when examined as a group.  Women in the current study 
who have had prophylactic surgery appear to have a greater sense of Mastery.  Items in 
the Mastery scale include:  “I am able to deal with my test result; I know my body well; I 
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am hopeful about myself in the future; I am in control of my health” (Esplen et al., 2009, 
p. 1224).  Items on the Stigma subscale include “I feel labeled; I feel different from 
others my age; I think about my test result a lot”.  In the perspective of self-concept, there 
would be a greater sense of Stigma indicated by the higher scores. 
Vodermaier et al. (2010) used the BRCA Self-Concept scale in a multisite 
Canadian study, including 241 women with a BRCA mutation; n =133 with a personal 
history of cancer.  Unaffected women in that study (n = 104) had Mastery scores of M = 
23.02 (SD = 4.04), and Stigma scores of M = 23.24 (SD = 10.84).  The results for the 
vulnerability subscale were not reported for that sample.  In contrast, the findings in this 
study sample (n = 223) for the Mastery scale were only M = 8.28 (SD = 4.12) and were 
more similar for the Stigma score, M =26.16 (SD= 9.97).  The average age of the 
unaffected participants in the Canadian study was 43.88 years; 39.5% of whom had not 
had any prophylactic surgery.   
Menopausal Symptoms 
Menopausal symptoms were more predominant in the prophylactic surgery group 
in this study; specifically hot flashes, night sweats and vaginal dryness on independent t-
tests.  The same PS group also had more difficulty with sleep, which could potentially 
impact other aspects of their lives.  Hierarchical multiple regression, controlling for age, 
found PS predictive for all menopausal symptoms and sleep difficulties.  Prophylactic 
surgery accounted for 15% of the variance in the hot flashes symptom, 12% for vaginal 
dryness, 7% of the variance for the night sweats symptom and 6% for the sleep 
difficulties.  Only 4% of the variance in bladder control was accounted for by PS.    
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Chapman et al. (2011) reported results of a small study (n =51) of both affected 
and unaffected BRCA+ women after BPSO; 47% were under the age of 50 at the time of 
the study.  Menopausal symptoms were assessed with a modified Menopause Symptoms 
List, including the symptoms of hot flashes, weight gain, vaginal dryness, low sex drive, 
uncomfortable sex, memory problems and depression.  The study participants reported an 
average of 3.5 menopausal symptoms, but details regarding the frequency or specific 
symptoms were not addressed.  In a prospective study using a pre/post-surgical study 
design, Finch et al. (2011b) also examined menopausal symptoms in affected and 
unaffected BRCA+ women undergoing BPSO (n =114).  A modified Menopause-
Specific Quality of Life measure was used to evaluate symptoms during the previous one 
week.  For those women experiencing surgical menopause after BPSO, vasomotor 
symptoms were significantly worse after surgery.  Vasomotor symptoms included hot 
flashes, night sweats and sweating.  Symptoms were also exacerbated in women with a 
prior history of breast cancer.  Hormone replacement therapy helped to improve the 
symptoms, but not to baseline levels.   
Sexual Functioning 
 The FSFI total score and domains of Desire, Arousal, Lubrication and Satisfaction 
were predicted by DAS in hierarchical multiple regression, while controlling for age, and 
also predicted by PS in a similar analysis.  Significant differences in the PS and NO PS 
groups were also seen on independent samples t-tests for the same FSFI dependent 
variables.  No differences were seen in the Orgasm or Pain domains for the 2 groups, nor 
were the findings significant in the hierarchical multiple regression.     
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 Prophylactic surgery explained a small portion of variance in the FSFI total score 
(4%) and the domain scores (3-8%).  However, the one-item DAS score explained 13% 
of the variance in the FSFI.   The DAS question specifically addresses the degree of 
happiness in one’s relationship.  A moderate positive correlation was seen between the 
DAS and total FSFI (r = .32), as well as the total QLI score (r =.46) and PGWBI (r =.48).    
Any PS had a smaller, negative correlation with FSFI (r = -.18).  Sexual functioning is a 
complex process.  Prophylactic surgery appears to have less to do with sexual functioning 
in the current study than one’s relationship status and overall well-being, as seen in other 
community-based research (Davison et al., 2009).   
Of note, estrogen replacement was used by 56.7% of the women who had BPSO 
(resulting in surgical menopause).  The effect of chemoprevention on sexual function was 
not evaluated.  Only a small fraction of women in this study sample were utilizing 
tamoxifen as a chemopreventive measure (1.7%).  In contrast, Schwartz et al. (2011) 
reported 17% use of tamoxifen or raloxifene in unaffected carriers participating in their 
study (n = 106), which also included BRCA+ women affected by breast or ovarian cancer 
(total N = 465).  
Satisfaction with Decision     
In this study sample, women who had undergone any prophylactic surgery were 
more satisfied with their decision than those who had not any risk-reducing surgery, 
significant on independent t-test.  Prophylactic surgery was also predictive of SWD on 
the hierarchical multiple regression, controlling for age.  This author hypothesizes the 
women who participated in this research may have had a preference for prophylactic 
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surgery over surveillance.  In the current study, the majority of women who had not any 
prophylactic surgery were intending to have surgery in the future (83%).   
Westin et al. (2011) also used the Satisfaction with Decision scale in research 
comparing women undergoing periodic screening with those choosing BPSO (n = 182).  
Levels of satisfaction with decision for the surgical group were also higher in that study.  
In a retrospective study of BRCA+ women after BPSO (n=98), 59.2% of women reported 
they would have preferred more information about sexual side effects prior to surgery 
(Campfield, Moyer, & Matloff, 2011).  Most participants in that study also indicated they 
would pursue the same surgery again (96.9%) and the majority would also recommend 
BPSO to other BRCA+ women in a similar situation (97.9%).  Finch et al. (2011b) found 
a decrease in sexual desire and an increase in vaginal dryness, as measured by the Sexual 
Activity Questionnaire in BRCA+ women after BPSO.  Overall, those women were also 
satisfied with the decision to undergo BPSO.  Measured with a study-specific satisfaction 
questionnaire, the participants reported a mean satisfaction score of 4.55 out of 5, with 5 
representing extremely satisfied. 
Moderating Role of Prophylactic Surgery 
No relationship was seen between FSFI, PGWBI, BRCA-SCC or BIQLI in 
combination with any prophylactic surgery and the total QLI when examined for 
interaction effects, independent of the effect of each variable alone.  There were 
significant main effects for the BRCA-SCC, the BIQLI/any prophylactic surgery, the 
FSFI/any prophylactic surgery, and the PGWBI total score.  This result parallels the lack 
of a significant difference between the PS and NO PS groups on all of the QOL measures 
in this current study, other than the Family subscale of the QLI measure.     
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Strengths 
 This research was innovative in the approach to initiate recruitment at a national 
conference, with subsequent ongoing web-based recruitment after the conference.  Study 
accrual was relatively rapid, and many participants provided commentary regarding their 
appreciation for research in this arena.  The BRCA Self-Concept Scale, a unique 
instrument only recently developed for use in this specific population, was utilized.  This 
study was also unique relative to the large sample size and inclusion of only unaffected 
BRCA+ women, without a personal history of cancer.  The majority of published studies 
have had smaller samples and included women with a personal history of breast or 
ovarian cancer.  These data contribute to our knowledge of quality of life, sexual 
functioning and psychological well-being in this population.  
Study Limitations 
These research findings are from a self-selected sample of women with a 
hereditary risk for breast and ovarian cancer.  Most participants became aware of this 
research effort through one organization, which could bias the results.  The data collected 
is entirely self-report.  There was no requirement to answer any research survey items, 
other than those required for informed consent and confirmation of eligibility with 
respect to the inclusion criteria.  Due to the nature of the research design, this cross-
sectional study does not allow for speculation relative to cause and effect.    
As a web-based research survey, individuals without access to the internet were 
unable to participate. In addition, intermittent problems with internet access to the study 
link could have prevented some individuals from either initiating or completing the study.  
Recruiting materials included the term previvor in an effort to use the lay language with 
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which this population self-identifies.  The term previvor, or presurvivor, describes an 
individual who does not have cancer, but possesses a genetic predisposition.  This 
expression may have been unfamiliar to some individuals, precluding participation or 
possibly confusing potential study participants.  The term previvor also implies a certain 
inevitability of a future cancer diagnosis, which is inaccurate in the face of a BRCA 
mutation.  This potential confusion may also account for the number of individuals who 
accessed the research study online in an attempt to participate, but were ineligible due to 
a personal history of cancer.       
The study participants were mostly Caucasian, well-educated, with health 
insurance and access to medical care.  They may not be representative of the larger 
population affected by hereditary breast and ovarian cancer.  They do, however, represent 
a large majority of women reported as undergoing genetic testing with BRACAnalysis®.   
Implications for Nursing  
Practice.  The results of this research contribute to our understanding of quality 
of life in BRCA+ women, particularly those opting for risk-reducing prophylactic 
surgery.  Evidence-based information is important for patient counseling, the informed 
consent process, and decision-making relative to risk management options.  After going 
through genetic testing, women with a BRCA mutation face difficult life choices.  
Accurate information regarding the potential risks and benefits relative to those choices is 
crucial.  Health care decisions impact their individual well-being, as well as that of their 
families and significant others.   
Counseling related to risk management is important for patients, couples, and 
families affected by hereditary breast and ovarian cancer.  Potential side effects related to 
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sexual functioning should be requisite in any discussion prior to prophylactic surgery.  
Symptom management and appropriate interventions relative to psychosocial well-being 
and sexual functioning can be tailored to meet the needs of individuals and couples.   
Ongoing assessment is important in order to provide timely, appropriate referrals for 
psychological counseling, support and/or consultation with a therapist competent in 
issues related to sexual health.   
Education.  Implications for nursing education include the importance of 
incorporating genetics and genomics into the curriculum.  A basic understanding is 
critical as the science advances and genetics/genomics become a tool in a broader 
spectrum of patient care.  Other important considerations include addressing nursing 
skills in risk assessment, patient counseling, communication, and human sexuality. 
Future research.  These data provide a foundation for future research.  A 
prospective longitudinal study, including measures both before and after prophylactic 
surgery, would provide more insight into the research questions.  Additional research is 
needed to focus on specific hormonal and non-hormonal symptom management 
interventions, to minimize the sequelae of prophylactic surgery related to female sexual 
functioning, menopausal symptoms and sleep disturbances.  Further investigation is 
needed to explore the discrepancy in the quality of life scores observed in the QLI and the 
SASS in this study.  Perhaps a mixed- methods design, incorporating focus groups could 
provide additional insight.  Little data are available for BRCA+ women older than 50 
years of age, often the parents of offspring of reproductive age who potentially carry a 
mutation themselves.  In addition, couples research could contribute to our knowledge 
and understanding of the dynamics of inherited cancer risk on the dyad.  All of these 
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individuals face unique challenges in the journey of living with a BRCA mutation.  As 
members of multidisciplinary clinical and research teams, nurses have a fundamental role 
in risk assessment, referral, education, and research to improve quality of life for this 
high-risk population.       
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Appendix A:  Web-based Survey Development Task List  
 
1. Develop dissertation research proposal. 
2. Defend proposal and obtain approval from Dissertation Committee.   
3. Secure funding for research. 
4. Develop study-specific Socio-Demographics/ Medical History/ Family Cancer 
History form. 
5. Obtain Institutional Review Board (IRB) approval at the University of South 
Florida. 
a. Continuing review approval after one year. 
6. Obtain letter of support from community agency (Facing Our Risk of Cancer 
Empowered; FORCE). 
7. Obtain password and secure training in Checkbox ® 4.6 Web Survey Software. 
8. Convert paper-based research instruments into web-based electronic survey 
format.  
a. Create conditional questions: 
i. Use question skip patterns as appropriate; develop survey 
algorithm so study participants only see relevant survey items.    
b. Score web-based survey items, using the previously validated research 
instruments.  
9. Test the web-based survey for functionality, clarity of items. 
a. Revise survey as indicated based on feedback from preliminary testing. 
10. Delete all test responses in the final data set. 
11. Secure physical space, tables, Wi-Fi internet access, computers, combination 
locks, Information Technology (IT) support and research study staff for 
recruitment 06/2011 at the Joining FORCEs Against Hereditary Cancer 
Conference venue (Hyatt Regency Grand Cypress, Orlando, Florida). 
12. Create separate e-mail account for study participants to submit e-mail address for 
random drawings ($100 e-cards). 
13. Establish automated response to any e-mails.  
14. Purchase domain name, with shortened URL for easy internet access to web-
based study. 
15. Create study recruitment materials. 
a. Obtain IRB approval for study recruitment materials and additional study 
personnel.   
16. Commence study recruitment. 
17. Export data files in SPSS .sav and Excel formats; secure data in password-
protected program.   
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Appendix A:  Web-based Survey Development Task List (Continued)  
18. Analyze data.   
19. Create spreadsheet for e-mail addresses submitted for e-card drawings. 
a. Random drawings for the $100 e-card, at intervals of every 75-80 
respondents. 
b. Notify by e-mail when selected; confirm redemption of e-card from 
Amazon.com 
c. Send second reminder if not redeemed; re-send gift card, as indicated.   
20. Periodic updates and announcements regarding ongoing research study 
recruitment to study via FORCE website and monthly newsletters.   
21. Contact other researchers, organizations, interested parties regarding study (as 
indicated).   
22. Respond to any e-mails and/or questions from participants or potential study 
participants (ongoing).  
23. Provide periodic progress reports to funding agencies:  American Cancer Society 
and the National Institute of Nursing Research and to Dissertation Committee.   
24. Disseminate research results:   
a. Poster presentation of preliminary findings at the International Society of 
Nurses in Genetics (ISONG); Montreal, Quebec, Canada (10/10/2011). 
b. Podium presentation of preliminary findings at the H. Lee Moffitt Cancer 
Center and Research Institute Nursing Research Day; Tampa, Florida, 
USA (10/28/2011).   
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Appendix B:  Socio-Demographics, Personal Medical History and  
Family Cancer History Form 
Current age 
 
Where do you live? 
State/Province; Country 
 
Last 4 digits of Social Security # /SIN 
 
How did you hear about this study? 
Website / Brochure/ Word of mouth / FORCE Conference/ Other 
 
Ethnicity:  Hispanic or Latina?   
 
Race: American Indian/Alaska Native 
Asian 
Native Hawaiian or Pacific Islander 
Black or African American 
White 
 
Education:  highest level completed  
Grade School 
Middle School  
 High School 
Technical School 
Some College 
Bachelor’s Degree 
Graduate Degree /Professional School  
 
Are you currently employed outside of the home? 
If no:  Are you seeking employment?  
Yes/ no; Retired? Student? Homemaker?  Other:   
If yes, then:   current occupation 
 
Marital status:  Single / Married / Separated/ Divorced / Widowed 
 
Are you in a committed relationship with a partner?  (yes/no) 
 
Do you currently have health insurance coverage? (yes/no) 
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Appendix B:  Socio-Demographics, Personal Medical History and  
Family Cancer History Form (Continued) 
 
Estimated distance to your primary health care provider? [Miles/Km ]   
Within 25 miles / 50-100 miles / 100-250 miles /more than 250 miles away 
Do you participate in a support group or community forum? 
Yes, in person / Yes, web-based / No 
 
Have any blood relatives been diagnosed with cancer? 
(Parents, Grandparents, aunts, Uncles, Siblings)  
 Yes/No/ Adopted or Unknown 
 
Ashkenazi Jewish heritage (yes/no) 
 
If you know any information about your biological family, please address the following 
as applicable. 
Maternal= Mom’s side of family / Paternal = Dad’s side of the family 
Type of cancer = primary site if known. 
Cancer type/ Age at diagnosis/ Still Living (yes/no) 
Mother 
Father 
Sister (s) 
Brother(s) 
Son(s) 
Daughter(s) 
 Maternal Grandmother 
Maternal Grandfather 
Maternal Aunt(s) 
Maternal Uncle(s) 
Maternal Cousin(s) 
Paternal Grandmother 
Paternal Grandfather 
Paternal aunt(s) 
Paternal Uncle(s) 
Paternal Cousin(s) 
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Appendix B:  Socio-Demographics, Personal Medical History and  
Family Cancer History Form (Continued) 
 
Height (inches/ centimeters) 
Weight (pounds/ kilograms) 
Any changes in weight over the past year? (yes/no) 
How much weight have you gained or lost? (amount) 
Was your change in weight intentional?  (yes/no) 
 
Have you been diagnosed with any of the following medical concerns?   
(Please check all that apply.) 
 Hypertension 
Heart problems 
High cholesterol 
Diabetes mellitus 
Thyroid problems 
Arthritis 
Headaches 
Depression 
Anxiety 
Endometriosis 
Uterine fibroids 
Osteoporosis 
Osteopenia 
Other:    
 
Gynecologic History: 
Age of first menstrual period 
Last menstrual period (month/year) 
Total # of pregnancies 
# of live births 
Age at first live birth?  
Irregular menstrual periods? 
Spotting or bleeding between periods? 
Vaginal bleeding or spotting with sexual intercourse? 
 
Are you pregnant now? (yes/no) 
Have you ever breastfed? (yes/no; for how long if applicable = # of months) 
Any plans for children in the future? (yes/no) 
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Appendix B:  Socio-Demographics, Personal Medical History and  
Family Cancer History Form (Continued) 
 
Any current contraception to prevent pregnancy? (yes/no) 
Current contraception methods. 
(Please check all that apply.) 
Condoms, vasectomy, bilateral tubal ligation, IUD, diaphragm, birth control pills, 
Depo-provera, patch, diaphragm,  tubal ligation, abstinence, other?  
 
Current prescription medications (yes/no) 
Birth control pills/ oral contraceptives 
Anti-anxiety 
Anti-depressants 
Estrogen 
Progesterone 
Testosteroe 
Tamoxifen/ How long have you taken Tamoxifen? (# of months) 
 
Any other prescription medications? 
Current over-the counter medication (herbs, calcium, vitamins, or supplements available 
without a prescription).  
Have you ever smoked cigarettes? (yes/no) 
Age when you started using tobacco? 
How many cigarettes daily? 
Other tobacco use? 
Total # of years smoked? 
If you have quit, age when you stopped using tobacco?  
 
Do you drink any alcohol? 
 Number of drinks per week? (Beer/ Wine/ Hard liquor)  
Do you exercise on a regular basis? (yes/no) 
 Please indicate type of exercise & # of days per week. 
 
Genetic testing results:   
BRCA 1 positive/ BRCA 2-positive /  
BRCA Variant of undetermined significance/ Other  
 
How long has it been since you received your genetic test results? 
0-6 months / 6-12 months/ 1-2 years/ 2-3 years/ 3-4 years/ 4-5 years/ > 5 years  
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Appendix B:  Socio-Demographics, Personal Medical History and  
Family Cancer History Form (Continued) 
 
Did you see a Genetic Counselor prior to testing for BRCA? (yes/no) 
Health care provider. 
Please tell us about your health care team. 
Indicate any providers you have seen in the past one year (may select more than 
one).  
Primary care provider; Obstetrician/ Gynecologist; Gynecologic 
Oncologist; Medical Oncologist; Surgical Oncologist; Breast Surgical 
Oncologist; General Surgeon; Plastic Surgeon; Psychiatrist; Psychologist; 
Mental Health Counselor    
 
Any other health care providers? 
 
Are you followed in a “High-Risk” clinic setting? (yes/no) 
Do you have a pelvic exam on a regular basis (with or without a Pap smear) 
 Yes- once yearly; Yes- every 6 months; No 
 
Do you have pelvic sonograms (ultrasound) on a regular basis?  
Yes- once yearly; Yes- every 6 months; Yes- more often; No 
Do you have a CA-125 blood level checked? 
 Yes- once yearly; Yes- every 6 months; No 
 
Have you ever had a bone density test? (DEXA/ bone densitometry) (Yes/no) 
Do you have breast imaging (mammogram, breast MRI &/or breast 
ultrasound/sonogram)? (yes/no) 
 Type & frequency of regularly scheduled breast imaging. 
 Once yearly (yes/no); every 6 months (yes/no) 
 
Have you had any prophylactic, risk-reducing surgery? (yes/no) 
Prophylactic mastectomy (yes/no) 
Procedure type / At what age.    
 Sentinel Lymph Node biopsy at the time of mastectomy?  (yes/no) 
 
Immediate breast reconstruction at the time of your mastectomy? (yes/no) 
 Type of reconstruction 
 Reconstruction completed?  (yes/no) 
Date of final procedure. 
 
Is there any surgery pending?  
 
Prophylactic surgery to remove fallopian tubes & ovaries (salpingo-oophorectomy) 
(yes/no) 
 Procedure type 
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Appendix B:  Socio-Demographics, Personal Medical History and  
Family Cancer History Form (Continued) 
 
Hysterectomy? (yes/no) 
 Procedure type; at what age? At same time as removal of tubes and ovaries? 
Any other surgical procedures?   
Procedure type/ At what age?  
 
Any complications related to your surgery (or surgeries)? 
 
What do you think was the primary reason you chose to have prophylactic, risk-reducing 
surgery? (What was your motivation for having surgery?)  
or 
What do you think is the primary reason you have decided not to have prophylactic 
surgery?  
Do you intend to have any risk-reducing surgery in the future? (yes/no) 
What surgery do you think you might have in the future? 
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Appendix C:  Quality of Life Index 
Ferrans and Powers 
QUALITY OF LIFE INDEX© GENERIC VERSION - III 
 
PART 1. For each of the following, please choose the answer that best describes how satisfied 
you are with that area of your life. Please mark your answer by circling the number. There are no 
right or wrong answers. 
 
Response options:  1= Very Dissatisfied 2= Moderately Dissatisfied 3= Slightly Dissatisfied 
4= Slightly Satisfied 5= Moderately Satisfied 6= Very Satisfied  
 
HOW SATISFIED ARE YOU WITH: 
1. Your health?  
2. Your health care?  
3. The amount of pain that you have?  
4. The amount of energy you have for everyday activities?  
5. Your ability to take care of yourself without help?  
6. The amount of control you have over your life?  
7. Your chances of living as long as you would like?  
8. Your family’s health?  
9. Your children?  
10. Your family’s happiness?  
11. Your sex life?  
12. Your spouse, lover, or partner?  
13. Your friends?  
14. The emotional support you get from your family?  
15. The emotional support you get from people other than your family?  
17. How useful you are to others?  
18. The amount of worries in your life?  
19. Your neighborhood?  
20. Your home, apartment, or place where you live?  
21. Your job (if employed)?  
22. Not having a job (if unemployed, retired, or disabled)?  
23. Your education 
24. How well you can take care of your financial needs?  
25. The things you do for fun?  
26. Your chances for a happy future?  
27. Your peace of mind?  
28. Your faith in God?  
29. Your achievement of personal goals?  
30. Your happiness in general?  
31. Your life in general?  
32. Your personal appearance?  
33. Yourself in general?  
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Appendix C:  Quality of Life Index (Continued) 
 
PART 2. For each of the following, please choose the answer that best describes how important 
that area of your life is to you. Please mark your answer by circling the number. There are no 
right or wrong answers. 
 
Response options:  1= Very Unimportant  2= Moderately Unimportant  3= Slightly Unimportant 
4= Slightly Important  5= Moderately Important  6= Very Important   
 
HOW IMPORTANT TO YOU IS: 
1. Your health?  
2. Your health care 
3. Having no pain?  
4. Having enough energy for everyday activities 
5. Taking care of yourself without help 
6. Having control over your life?  
7. Living as long as you would like?  
8. Your family’s health?  
9. Your children?  
10. Your family’s happiness 
11. Your sex life?  
12. Your spouse, lover, or partner?  
13. Your friends?  
14. The emotional support you get from your family 
15. The emotional support you get from people other than your family?  
16. Taking care of family responsibilities 
17. Being useful to others 
18. Having no worries?  
19. Your neighborhood 
20. Your home, apartment, or place where you live?  
21. Your job (if employed)? 
22. Having a job (if unemployed, retired, or disabled). 
23. Your education?  
24. Being able to take care of your financial needs?  
25. Doing things for fun?  
26. Having a happy future 
27. Peace of mind 
28. Your faith in God?  
29. Achieving your personal goals?  
30. Your happiness in general?  
31. Being satisfied with life?  
32. Your personal appearance?  
33. Are you to yourself?  
 
© Copyright 1984 & 1998 Carol Estwing Ferrans and Marjorie J. Powers 
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Appendix D:  Self-Anchoring Striving Scale 
 
 
We all desire certain things out of life.  When you think about what really matters 
in your own life, where on the ladder would you place your life at the present 
time?  
   
10 = the best you can imagine  
 
 
10 
9 
8 
7 
6 
5 
4 
3 
2 
1 
    
  
1 = the worst you can imagine.  
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Appendix E:  Dyadic Adjustment Scale  
(One-item: Happiness)  
 
 
 
 
There are different degrees of happiness in relationships. The middle point, 
"happy," represents the degree of happiness in most relationships. Please circle 
the number that best describes the degree of happiness, all things considered, of 
your relationship at the present time. 
 
               0             1                 2              3              4               5               6 
               |               |                  |               |                |               |                 |              
        
    Extremely     Fairly           A Little      Happy       Very       Extremely   Perfect 
    Unhappy      Unhappy      Unhappy                    Happy    Happy 
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Appendix F:  Body Image Quality of Life Inventory 
 
Instructions:  Different people have different feelings about their physical 
appearance. These feelings are called “body image.” Some people are generally 
satisfied with their looks, while others are dissatisfied. At the same time, people 
differ in terms of how their body-image experiences affect other aspects of their 
lives. Body image may have positive effects, negative effects, or no effect at all. 
Listed below are various ways that your own body image may or may not 
influence your life. For each item, circle how and how much your feelings about 
your appearance affect that aspect of your life. Before answering each item, think 
carefully about the answer that most accurately reflects how your body image 
usually affects you. 
 
- 3= Very Negative Effect; -2= Moderate Negative Effect; -1=Slight Negative 
Effect; 0= No effect; +1= Slight Positive Effect; +2=Moderate Positive Effect;  
+3= Very Positive Effect  
 
1. My basic feelings about myself—feelings of personal adequacy and self-worth 
2. My feelings about my adequacy as a man or woman—feelings of masculinity 
or femininity.  
3. My interactions with people of my own sex.  
4. My interactions with people of the other sex.  
5. My experiences when I meet new people.  
6. My experiences at work or at school.  
7. My relationships with friends.  
8. My relationships with family members.  
9. My day-to-day emotions.  
10. My satisfaction with my life in general.  
11. My feelings of acceptability as a sexual partner.  
12. My enjoyment of my sex life.  
13. My ability to control what and how much I eat.  
14. My ability to control my weight.  
15. My activities for physical exercise.  
16. My willingness to do things that might call attention to my appearance.  
17. My daily “grooming” activities (i.e., getting dressed and physically ready 
for the day).  
18. How confident I feel in my everyday life.  
19. How happy I feel in my everyday life. 
 
(©TF Cash, 2002) 
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Appendix G:  Female Sexual Functioning Index 
 
INSTRUCTIONS: These questions ask about your sexual feelings and responses 
during the past 4 weeks. Please answer the following questions as honestly and 
clearly as possible. Your responses will be kept completely confidential. In 
answering these questions the following definitions apply: 
 
Sexual activity can include caressing, foreplay, masturbation and vaginal intercourse. 
 
Sexual intercourse is defined as penile penetration (entry) of the vagina. 
 
Sexual stimulation includes situations like foreplay with a partner, self-stimulation 
(masturbation), or sexual fantasy. 
 
CHECK ONLY ONE BOX PER QUESTION. 
 
Sexual desire or interest is a feeling that includes wanting to have a sexual 
experience, feeling receptive to a partner's sexual initiation, and thinking or 
fantasizing about having sex. 
 
1. Over the past 4 weeks, how often did you feel sexual desire or interest? 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
2. Over the past 4 weeks, how would you rate your level (degree) of sexual 
desire or interest? 
Very high 
High 
Moderate 
Low 
Very low or none at all 
 
Sexual arousal is a feeling that includes both physical and mental aspects of sexual 
excitement. It may include feelings of warmth or tingling in the genitals, lubrication 
(wetness), or muscle contractions. 
 
3. Over the past 4 weeks, how often did you feel sexually aroused ("turned   
on") during sexual activity or intercourse? 
No sexual activity 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
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Appendix G:  Female Sexual Functioning Index (Continued) 
 
 
4. Over the past 4 weeks, how would you rate your level of sexual arousal 
("turn on") during sexual activity or intercourse? 
No sexual activity 
Very high 
High 
Moderate 
Low 
Very low or none at all 
 
5.  Over the past 4 weeks, how confident were you about becoming sexually 
 aroused during sexual activity or intercourse? 
No sexual activity 
Very high confidence 
High confidence 
Moderate confidence 
Low confidence 
Very low or no confidence 
 
6. Over the past 4 weeks, how often have you been satisfied with your arousal 
(excitement) during sexual activity or intercourse? 
No sexual activity 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
7.  Over the past 4 weeks, how often did you become lubricated ("wet") during 
sexual activity or intercourse? 
No sexual activity 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
8. Over the past 4 weeks, how difficult was it to become lubricated ("wet") 
during sexual activity or intercourse? 
No sexual activity 
Extremely difficult or impossible 
Very difficult 
Difficult 
Slightly difficult 
Not difficult 
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Appendix G:  Female Sexual Functioning Index (Continued) 
 
9. Over the past 4 weeks, how often did you maintain your lubrication 
("wetness") until completion of sexual activity or intercourse? 
No sexual activity 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
10.  Over the past 4 weeks, how difficult was it to maintain your lubrication 
("wetness") until completion of sexual activity or intercourse? 
No sexual activity 
Extremely difficult or impossible 
Very difficult 
Difficult 
Slightly difficult 
Not difficult 
 
11. Over the past 4 weeks, when you had sexual stimulation or intercourse, how 
often did you reach orgasm (climax)? 
No sexual activity 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
12. Over the past 4 weeks, when you had sexual stimulation or intercourse, how 
difficult was it for you to reach orgasm (climax)? 
No sexual activity 
Extremely difficult or impossible 
Very difficult 
Difficult 
Slightly difficult 
Not difficult 
 
13. Over the past 4 weeks, how satisfied were you with your ability to reach 
orgasm (climax) during sexual activity or intercourse? 
No sexual activity 
Very satisfied 
Moderately satisfied 
About equally satisfied and dissatisfied 
Moderately dissatisfied 
Very dissatisfied 
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Appendix G:  Female Sexual Functioning Index (Continued) 
 
14. Over the past 4 weeks, how satisfied have you been with the amount of 
emotional closeness during sexual activity between you and your partner? 
No sexual activity 
Very satisfied 
Moderately satisfied 
About equally satisfied and dissatisfied 
Moderately dissatisfied 
Very dissatisfied 
 
15. Over the past 4 weeks, how satisfied have you been with your sexual 
relationship with your partner? 
Very satisfied 
Moderately satisfied 
About equally satisfied and dissatisfied 
Moderately dissatisfied 
Very dissatisfied 
 
16. Over the past 4 weeks, how satisfied have you been with your overall sexual 
life? 
Very satisfied 
Moderately satisfied 
About equally satisfied and dissatisfied 
Moderately dissatisfied 
Very dissatisfied 
 
17. Over the past 4 weeks, how often did you experience discomfort or pain 
during vaginal penetration? 
Did not attempt intercourse 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
 
18.  Over the past 4 weeks, how often did you experience discomfort or pain 
following vaginal penetration? 
Did not attempt intercourse 
Almost always or always 
Most times (more than half the time) 
Sometimes (about half the time) 
A few times (less than half the time) 
Almost never or never 
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Appendix G:  Female Sexual Functioning Index (Continued) 
 
19. Over the past 4 weeks, how would you rate your level (degree) of discomfort 
or pain during or following vaginal penetration? 
Did not attempt intercourse 
Very high 
High 
Moderate 
Low 
Very low or none at all 
 
 
 
If no sexual activity during the past 4 weeks, please indicate the reason  
(may choose more than one): 
 
Not really interested in sex    ○ 
Physical problems related to sex   ○ 
Lack of a partner     ○ 
Partner has physical problems related to sex ○ 
Partner is not interested in sex      ○   
Other: __________________________ 
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Appendix H:  Menopausal Symptom Scale  
 
Below is a list of symptoms that you may have experienced during the week. 
Please rate how bothered you were each by each problem during the last week 
by circling one number for each symptom. 
 
Not at all Slightly     Moderately  Quite a bit  Extremely 
1  2        3      4        5 
 
Hot flashes 
Night sweats 
Vaginal dryness 
Genital itching/irritation 
Pain in pelvic area 
Difficulty with bladder control while laughing or crying 
Difficulty with bladder control at other times 
Sleep problems (difficulty falling asleep, sleeping through the night, waking up early) 
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Appendix I:  Psychological General Well-Being Index (Revised)  
 
 *Questions are to be answered for how you have felt during the past week.  
 
1. Did you feel in good spirits?  
2. Have you been bothered by any illness, bodily disorder, aches or pains?  
3. Have you felt depressed?  
4. Have you been in firm control of your behavior, thoughts, emotions or feelings?  
5. Have you been bothered by nervousness or your ‘nerves’?  
6. Did you have a lot of energy, pep or vitality?  
7. Have you felt downhearted and blue?  
8. Have you been generally tense or did you feel any tension?  
9. Have you been happy, satisfied, or pleased with your personal life?  
10. Did you feel healthy enough to carry out the things you like to do or had to do?  
11. Have you felt sad, discouraged, hopeless, or had so many problems that you wondered if 
anything was worthwhile?  
12. Have you been waking up feeling fresh and rested?  
13. Have you been concerned, worried or had any fears about your health?  
14. Have you had any reason to wonder if you were losing your mind, or losing control over the 
way you act, talk, think, feel or of your memory?  
15. Has your daily life been full of things that were interesting to you?  
16. Did you feel dull or sluggish?  
17. Have you been anxious, worried, or upset?  
18. Have you been feeling emotionally stable and sure of yourself?  
19. Did you feel relaxed and at ease?  
20. Have you felt cheerful and lighthearted?  
21. Have you felt tired, worn out, used up or exhausted?  
22. Have you been under, or felt you were under any strain, stress or pressure?  
 
Response options (# 1,3,5,7,9,11,13,15,17,19,21): None of the time; A little of the time; Some of 
the time; A good bit of the time; Most of the time; All of the time  
Response options (# 2,4,6,8,10,12,14,16,18,20,22): All of the time; Most of the time; A good bit 
of the time; Some of the time; A little of the time; None of the time  
Scoring: Reverse items 3,4,5,6,7,10,11,12,13,17,18,20,21  
Subscale composition:  
Anxiety—5,8,17,19,22  
Depressed Mood—3,7,11  
Positive Well-Being—1,9,15,20  
Self-Control—4,14,18  
General Health—2,10,13  
Vitality—6,12,16,21 
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Appendix J:  BRCA Self-Concept Scale 
 
Instructions: Below is a list of statements that people sometimes make about themselves. Please 
read each statement and decide if you agree or disagree and to what extent. If you strongly 
disagree circle 1, if you strongly agree circle 7, if you are somewhere in between circle any of the 
other numbers between 1 and 7, number 4 is the midpoint. If the statement does not apply to you 
please circle 8 for not applicable.  
 
1. I am hopeful about myself in the future (R)  
2. I am able to deal with my test result (R)  
3. I feel my body has betrayed me  
4. I feel like a walking time bomb  
5. I feel different from others my age  
6. I know my body well (R)  
7. I feel guilty that I might pass on a cancer risk to my children  
8. I feel isolated because of my test result  
9. I feel I have lost my sense of privacy  
10. I think about my test result a lot  
11. I am worried that cancer will be found when I go for screening  
12. I feel labeled  
13. I feel burdened with this information  
14. I distrust my body  
15. I am in control of my health (R)  
16. My test result gets in the way of who I really am  
17. I have become more secretive     (R) indicates item to be recoded. 
 
  
108 
 
 
 
 
 
 
Appendix K:  Satisfaction with Decision  
 
Please answer the following questions regarding your decision on how to manage your 
hereditary risk for cancer.   
 
Please indicate to what extent each statement is true for you AT THIS TIME.   
Use the following scale to answer the questions.  
1 = strongly disagree 
2= disagree 
3=neither agree nor disagree 
4= agree 
5= strongly agree 
 
1. I am satisfied that I am adequately informed about the issues important to my 
decision. 
 
2. The decision I made was the best decision possible for me personally. 
 
3. I am satisfied that my decision was consistent with my personal values. 
 
4. I expect to successfully carry out (or continue to carry out) the decision I made. 
 
5. I am satisfied that this was my decision to make. 
 
6. I am satisfied with my decision.   
 
 
 
